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SUMMARY 
The effects of posture and sleep on the pharmaco-
kinetics of five drugs (benzylpenicillin, gentamicin, 
sulphamethoxazole, trimethoprim and paracetamol) 
especially chosen for their disposition 
characteristics, were studied. To assess these 
effects, the drugs were administered, on separate 
occasions, to healthy young adults during ambulation, 
daytime bedrest and, with the exception of benzyl-
penicillin, sleep. In addition, benzylpenicillin 
pharmacokinetics were determined following both intra-
venous and intramuscular administration to the same 
subjects. 
New or improved high-performance liquid chromatography 
assays were developed for the determination of these 
drugs in biological fluids. Pharmacokinetic analysis 
of the drug concentration-time data was performed using 
traditional compartmental methods as well as a non-
compartmental method using statistical moment theory. 
Generally, the results showed that posture had the 
greatest influence on the disposition of drugs with low 
renal extraction ratios and that sleep appears to have 
the same effects as bedrest on pharmacokinetics. 
With gentamicin, a highly polar compound with a low 
renal extraction ratio, ambulant subjects exhibited a 
larger volume of distribution and clearance than supine 
subjects. These findings may be due to posture-induced 
alterations in tissue perfusion and extracellular fluid 
distribution rather than to changes in renal function. 
These results may be clinically important; especially 
the finding that gentamicin C 2 had a longer mean 
residence time than the other major components since it 
has been suggested, recently, that gentamicin C 2 is the 
most nephrotoxic of the components. 
Sulphamethoxazole, a weak acid, was found to have a 
shorter half-life and greater urinary excretion rate 
during bedrest than during ambulation and a direct 
relationship was shown between the urinary excretion 
rate of the drug and both urinary pH and urine flow. 
Both these factors had higher values during bedrest. 
Trimethoprim, a weak base, is less sensitive to urine pH 
changes over the range observed and, consequently, the 
disposition of this drug was unaffected by posture or 
sleep. 
Unlike gentamicin and sulphamethoxazole, the pharmaco-
kinetics of benzylpenicillin and paracetamol were 
unaffected by posture. Although the mean plasma 
benzylpenicillin levels were lower for bedrest than for 
ambulation, there were no significant differences 
between ambulation and bedrest for any of the derived 
pharmacokinetic parameters and thus it is suggested 
that the posture-dependent changes in the disposition 
of the penicillins reported by other workers may be 
related to the level of exercise undertaken in those 
studies. 
Paracetamol elimination was affected by neither change•
of posture nor sleep but the rate of absorption 
appeared to be slowest during sleep. These findings 
are in accordance with the low hepatic extraction ratio 
of paracetamol and the slower gastric emptying in 
supine and sleeping subjects. 
Overall, therefore, these studies show that change of 
posture can cause significant changes in the pharmaco-
kinetics of certain drugs, especially polar compounds 
with low renal clearance and weak acids whose 
elimination is sensitive to changes in urine pH and 
urine flow. In conclusion, it is recommended that the 
posture of the patient should be taken into account in 
the design of pharmacokinetic studies and dosage 
regimes. 
This thesis contains no material which 
has been accepted for the award of any 
degree or diploma in any College or 
University. 
To the best of my knowledge and belief, 
this thesis contains no material 
previously published or written by 
another person, except when due reference 
is made in the text of the thesis. 
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CHAPTER 1 
INTRODUCTION 
1.1: INTRODUCTION 
The impetus for these studies came from two queries directed 
at staff at the School of Pharmacy, University of Tasmania. 
Both queries, one from hospital pharmacy and the other from 
community pharmacy, were concerned with the necessity to 
maintain a strict dosage regime day and night even if it 
meant waking the patient. 
The determination of a dosage regime to achieve suitable 
drug levels in the body at specific times of the day may be 
based on the pharmacokinetics of the drug. The 
pharmacokinetics of a particular drug depends on both the 
physico-chemical properties of the drug and the 
physiological features of the person to whom it is 
administered. Many factors including age, disease, other 
drugs, posture, sleep and exercise may affect the 
physiological variables on which the disposition of the drug 
depends. 
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1.2: PHYSIOLOGICAL FACTORS AFFECTING PHARMACOKINETICS 
1.2.1: FACTORS AFFECTING ABSORPTION 
The great majority of drugs are administered extravascularly 
and are intended to act systemically. For these drugs, 
absorption into the systemic circulation is required before 
the drug can exert its pharmacological effect. Changes in 
the onset, rate and extent of absorption may contribute to 
the variability in drug response which may, occasionally, 
result in toxicity or therapeutic failure. 
1.2.1.1: GASTROINTESTINAL ABSORPTION 
Most drugs are administered orally and the small intestine 
is the foremost site of absorption, with very little drug 
being absorbed from the stomach (Hirtz, 1985). 
Consequently, the rate of movement of drug into the small 
intestine determines the time of onset, rate and, 
occasionally, extent of absorption. Gastric emptying may be 
affected by many factors. The nature and volume of the 
gastric contents can have a marked effect. Liquids are 
emptied faster than solids and it has been suggested that 
the pylorus has a screening effect for solid particles 
larger than 2mm (Hirtz, 1985). Several studies have shown 
that drugs are absorbed more rapidly, although not 
necessarily more completely, if administered on an empty 
stomach. Divoll et al (1982) and Heading et al (1973) 
observed that paracetamol was absorbed more slowly when 
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administered with food than when it was administered to 
fasting subjects. 
The rate of gastric emptying is slowed by drugs such as 
propantheline and narcotic analgesics thus delaying 
absorption of other drugs (Clements et al, 1978; Nimmo, 
1976) while metoclopramide enhances gastric emptying 
resulting in accelerated absorption of drugs (Nimmo, 1976). 
Disease can also either enhance or slow the gastric emptying 
rate. Chronic calcular cholecystitis increases the rate of 
gastric emptying (Nimmo, 1976) while various other 
conditions including diabetes mellitus, myxoedema, 
malnutrition (Nimmo, 1976), migraine (Volans, 1974) and 
cardiac failure (Benet, Greither & Meister, 1976) retard the 
passage of gastric contents into the duodenum. 
Gastric emptying is slower in bedrested subjects than 
ambulant or upright subjects. Even the postion in which a 
subject lies can influence gastric emptying rate. Yu (1975) 
observed that, in neonates, the stomach emptied more rapidly 
in the prone and right lateral positions than in the supine 
and left lateral positions. More recently, Burn-Murdoch, 
Fisher & Hunt (1980) found that the rate of gastric emptying 
of a saline solution was faster in subjects who were lying 
on their right side than in subjects sitting which, in turn, 
was faster than in subjects lying on their left side. 
However, when the administered solution contained glucose 
(100g/1), posture had no effect on the rate of gastric 
emptying, possibly because feedback mechanisms from duodenal 
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receptors controlled the emptying of the energy-dense meal 
(Burn-Murdoch et al, 1980). Slower onset of absorption in 
supine subjects than in ambulant subjects has been found for 
paracetamol (Nimmo & Prescott, 1978), amoxycillin (Roberts & 
Denton, 1980), theophylline (Warren, Cuss & Barnes, 1985) 
and zopiclone (Channer, Dent & Roberts, 1984). Roberts & 
Denton (1980) also found that when amoxycillin was 
administered immediately prior to sleep, the lag time for 
the onset of absorption was longer than for bedrested 
subjects, suggesting even slower gastric emptying during 
sleep. 
The bioavailability of acid-labile drugs and drugs 
metabolised while in the gastrointestinal tract, such as 
penicillin, erythromycin and levodopa, may be reduced when 
gastric emptying is slow. On the other hand, for poorly-
soluble drugs such as griseofulvin , nitrofurantoin, and 
digoxin, and drugs whose absorption is saturable, for 
example riboflavin, a slow rate of gastric emptying actually 
increases the extent of absorption by providing either a 
greater opportunity for the drug to dissolve or longer 
contact time between the drug and the absorption sites 
(Gibaldi, 1984). The bioavailability of most drugs is 
usually unaffected by the rate of gastric emptying. 
Once a drug has entered the intestine, it must pass through 
the intestinal wall into the blood of the portal vein and be 
transported to the liver before entering the systemic 
circulation. Even though gastrointestinal absorption of a 
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drug may be complete, the extent of absorption of intact 
drug into the systemic circulation may be less than complete 
if the drug is metabolised by enzymes in either the gut wall 
or the liver. The presystemic clearance depends on several 
physiological factors, including enzyme capacity of the gut 
wall and of the liver, splanchnic blood flow, plasma protein 
binding and gastrointestinal motility (Pond & Tozer, 1984). 
Many clinically important drugs undergo considerable 
presystemic clearance after an oral dose. Some examples of 
these drugs are propranolol, metoprolol, amitriptyline, 
hydralazine, morphine, lignocaine, organic nitrates and 
nifedipine. 
The enzyme-inducing effects of drugs and smoking have been 
reported to result in reduced bioavailability of alprenolol 
and lignocaine (Pond & Tozer, 1984). Reduced enzyme 
capacity of the liver may account for the increased 
bioavailability of chlormethiazole, labetolol, metoprolol, 
dextropropoxyphene and propranolol in patients with 
cirrhosis of the liver (Blaschke & Rubin, 1979). 
Blood flow assures continuous absorption by removing the 
drug that passes through the gastrointestinal membrane. 
With highly lipid-soluble drugs, penetration may be so rapid 
that the absorption becomes perfusion-limited (Rowland & 
Tozer, 1980a). Fgod causes a transient increase in the 
splanchnic blood flow. Svensson et al (1983) observed that 
the splanchnic blood flow was elevated for 280 minutes with 
a mean increase of 69% at 40 minutes following a high-
protein meal. The bioavailability of propranolol (McLean et 
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al, 1981; Jackman et al, 1981), metoprolol and hydralazine 
(Melander, 1978) is higher when the drug is administered 
with food, although Walden et al (1981) did not find a 
significant increase in hydralazine bioavailability in 
subjects dosed one hour after food. McLean et al (1978) 
showed by computer simulation that these results may be due 
to the transient nature of the increase in splanchnic blood 
flow. Not all drugs which undergo extensive presystemic 
clearance have an increased bioavailability when 
administered with food. This has been found for prazosin, 
amitriptyline and dextropropoxyphene (Melander & McLean, 
1983). Liver blood “low is reduced in.:;cardiac failure 
(Benet et al, 1976) and may be altered in an unpredictable 
manner in liver disease (Pond & Tozer, 1984). 
Changes in posture and exercise alter hepatic blood flow 
but, so far, there are no reports on posture, sleep or 
exercise modifying the bioavailability of a drug through 
altered splanchnic blood flow. The effects of posture and 
exercise on hepatic blood flow are discussed further in 
section 1.2.3. 
1.2.1.2: INTRAMUSCULAR ABSORPTION 
The second most common site of extravascular administration 
of drugs intended to have a systemic action is 
intramuscular. 
The usual sites of injection are the arm (deltoid), lateral 
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thigh (vastus lateralis) or the buttocks (gluteus maximus). 
The effect of injection site on the rate of absorption of 
drugs has been studied by several workers. Injections into 
the thigh result in higher plasma drug concentrations than 
injections into the buttocks for diazepam (Assaf, Dundee & 
Gamble, 1974), cephacetrile, gentamicin and cephaloridine 
(Reeves et al, 1974). Injection into the deltoid gave 
higher lignocaine peak plasma concentrations than thigh 
injection which, in turn, gave higher concentrations than 
injection into the buttocks (Cohen et al, 1972; Schwartz et 
al, 1974). These findings correlate well with the rank 
order of the blood flow to each muscle group determined by 
Evans et al (1975) using the 133  Xenon washout technique. In 
an earlier work, Bederka, Takemori & Miller (1971) injected 
a variety of substances (molecular weights 20 - 585) into 
muscle of rats and concluded that muscle blood flow rather 
than diffusion is the rate-limiting step for the absorption 
of drugs administered intramuscularly. Variation in muscle 
blood flow was regarded as being the major reason for the 
considerable variation observed in the disposition of 
morphine injected into the gluteus maximus (Rigg et al, 
1978). 
On moving from the supine to an upright position, there is a 
shift of blood flow away from the liver and kidneys 
(Culbertson et al, 1951; Chapman et at, 1948). No details 
appear to be available on the effect of posture alone on 
skeletal muscle flow. Exercise certainly causes an 
increased blood flow to the working muscle. Ahlborg & Felig 
(1982) reported a seven-fold increase in leg muscle blood 
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flow during bicycle exercise. Riches (1954) observed higher 
plasma levels of streptomycin in active, ambulant patients 
than when the patients remained at rest. Also, Schmidt & 
Roholt (1966) found higher and earlier peak benzylpenicillin 
concentrations in ambulant patients than in the same 
patients when bedrested, indicating a faster rate of 
absorption of the drug during exercise. 
1.2.2: FACTORS AFFECTING DISTRIBUTION 
The pharmacokinetic parameter which characterizes the 
distribution of a drug is the apparent volume of 
distribution (V) which is used to relate the plasma 
concentration (C) to the amount of drug in the body (Ab) 
(V=Ab/C). The apparent volume of distribution rarely 
corresponds to a real volume. Drug distribution may be to 
any combination of tissues and fluids in the body and there 
are many factors that can affect the determined apparent 
volume of distribution. 
Drugs are distributed throughout the body by means of the 
blood circulation. Almost all drugs easily cross capillary 
walls and enter the extracellular fluid except in 
specialized regions such as the brain where the capillaries 
differ in their permeability characteristics and, so, 
present a barrier to drugs not having lipophilic properties. 
Movement of drugs from the extracellular fluid into cells 
depends on the physico-chemical properties of the drugs and 
the extracellular pH. Blood flow, then, is the rate- 
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limiting step in the distribution of most drugs into the 
tissues. Polar drugs diffusing across tightly knit lipoid 
membranes are the exception. In cardiac failure, 
autoregulation maintains a relatively normal blood flow to 
the brain and myocardium and relatively less to the kidney, 
muscle and splanchnic tissues (Benowitz & Meister, 1976). 
Changes in the distribution of procainamide, quinidine, 
lignocaine and digoxin have been reported in patients with 
cardiac failure (Wilkinson, 1976; Benowitz & Meister, 1976). 
Swartz & Sidell (1973) found that, under conditions of heat 
and exercise stress, the volumes of distribution for 
pralidoxime and p-aminohippurate increased, particularly the 
volume of the tissue compartment. It was suggested that, 
due to the altered blood flow during exercise and stress, 
the drugs were distributed to tissues not receiving much 
drug at rest. 
For water-soluble drugs, changes in the extracellular fluid 
volume can alter their apparent ditribution. The 
extracellular fluid volume is expanded in cardiac failure 
(Benowitz, 1984) and following a high salt intake (Gauer, 
Henry & Behn, 1970). Neonates and young children have a 
higher proportion of their body mass as water than adults 
while in the elderly this proportion is smaller than in 
young adults (Klotz, 1976). On adopting an upright position 
there is a shift of plasma fluid from the vascular system to 
the interstitial space. Nearly 500m1 may leave the 
vasculature after sixty minutes standing (Hagan, Diaz & 
Horvath, 1978). Exercise causes a further shift of fluid. 
Greenleaf et al (1979) observed a decrease in plasma volume 
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of greater than 500m1 in subjects undertaking supine 
exercise. Prescott (1975) reported higher plasma levels of 
paracetamol in bedrested patients than in ambulant subjects. 
As there were no differences in the rates of absorption or 
elimination between the two groups, these results were 
attributed to a larger volume of distribution in ambulant 
subjects due to either increased peripheral perfusion or a 
shift in plasma fluids associated with the change of posture 
and exercise. 
The movement of fluid from the vascular system with change 
of posture or exercise also results in haemoconcentration 
with the most pertinent change being an approximately 21% 
increase in plasma protein concentration (Hagan et al, 
1978). The plasma concentration of drugs highly bound to 
plasma proteins would increase during haemoconcentration 
resulting in a smaller apparent volume of ditribution. 
Dettli & Spring (1966) observed an apparently very low 
elimination rate of sulphasymazine in patients who got out 
of bed before a twelve-hour sample was taken. They 
attributed these findings to the effect of haemo-
concentration. Half of the extracellular protein is found 
in the interstitial fluid with a large proportion of it 
being in the skin and muscle due to the large volumes of 
extracellular fluid in these tissues (Gauer et al, 1970). 
Prolonged bedrest or immobilisation produces a shift of 
protein to the extravascular areas. This also occurs 
following extensive burns as a result of increased capillary 
permeability (Jusko, 1976). 
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Many drugs have a high affinity for tissue proteins so any 
displacement of drug from these binding sites will affect 
plasma levels and the apparent volume of distribution of the 
drug. Pedersen et al (1983) observed a rise of 63% in 
plasma digoxin levels when subjects were immobilised for two 
hours following normal physical activity. On resumption of 
normal activities and with strenuous exercise, the plasma 
digoxin levels gradually declined to the pre-immobilisation 
levels. Changes in tissue binding of the drug were 
considered to be the cause of the observed plasma level 
changes. 
1.2.3: FACTORS AFFECTING HEPATIC ELIMINATION 
Most drugs are metabolised to some extent with the liver 
being the major site of drug metabolism, although this may 
also occur in several other tissues. 
The hepatic clearance of a drug depends on three 
physiological variables -- the blood flow to the liver; the 
intrinsic ability of the liver to irreversibly metabolise 
the drug; and the binding of the drug to plasma proteins and 
cellular components in the blood (Nies, Shand & Wilkinson, 
1976). The clearance of drugs of high hepatic extraction 
ratio is dependent on liver blood flow because the flow is 
small relative to ,the intrinsic ability of the liver to 
remove the drug. For drugs of low extraction ratio, the 
intrinsic ability of the liver to remove the drug is small 
relative to the blood flow and the clearance of these drugs 
is independent of liver blood flow (Rowland & Tozer, 1980b). 
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Factors which alter hepatic blood flow will affect the 
disposition of drugs with flow-dependent clearance such as 
lignocaine, verapamil, many beta-adrenergic blocking agents, 
narcotic analgesics and tricyclic antidepressants (George, 
1979). The hepatic blood flow decreases in the elderly 
resulting in a reduction in the clearance of propranolol, 
lignocaine and chlormethiazole (George, 1979). The 
influence of hepatic disease on hepatic blood flow is 
complex. It appears, however, that hepatic blood flow is 
reduced in patients with chronic liver disease and, as a 
consequence, the clearance of many highly extracted drugs is 
also reduced in these patients (Williams, 1984). Pessayre 
et al (1978) determined that the reduced clearance of d-
propranolol in cirrhotic patients was due to a combination 
of impaired ability of the liver to metabolise the drug and 
reduced liver blood flow. The clearance of intravenously 
administered lignocaine is lower in patients with cardiac 
failure as this disease causes a drop in liver blood flow in 
proportion to the cardiac index (Benowitz & Meister, 1976). 
Culbertson et al (1951) examined the effect of posture on 
hepatic blood flow and observed a decrease in estimated 
liver blood flow of approximately 38% when subjects adopted 
an upright postue. In a study on the effect of posture on 
the elimination of a high hepatic extraction ratio drug, 
midazolam, the clearance of the drug in supine subjects was 
about twice that observed in ambulant subjects (Klotz & 
Ziegler, 1982). The liver blood flow also falls during 
exercise. Lundbergh & Strandell (1974) observed a 39% fall 
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in liver blood flow in normal subjects and a 59% fall in 
patients with infectious hepatitis during supine exercise. 
Swartz, Sidell & Cucinell (1974) examined liver blood flow 
during exercise, heat and fluid-restriction stresses using 
indocyanine green clearance as the indicator of liver blood 
flow. Indocyanine green clearance decreased with increasing 
stress. In the same set of experiments, the disposition of 
antipyrine, a low extraction ratio drug, was not greatly 
affected by these changes in liver blood flow. 
It is generally considered that only drug not bound to 
plasma proteins is available for elimination by the liver. 
Since dissociation from protein is very rapid, changes in 
protein binding usually have no effect on the elimination of 
drugs with high extraction ratio but the clearance of drugs 
with low extraction ratio and high affinity for plasma 
proteins will be sensitive to changes in the extent of 
protein binding. Factors affecting protein binding have 
already been discussed (section 1.2.2). The clearance of 
warfarin, disopyramide and phenprocoumon have been shown to 
vary with the fraction unbound (Tozer, 1984). 
Drugs with low hepatic extraction ratio are also sensitive 
to changes in the intrinsic clearance ability of the liver. 
The intrinsic clearance can be enhanced by factors that 
induce the activity of drug-metabolising enzymes and reduced 
by factors that inhibit those enzymes. Paracetamol has been 
used as a model drug for type II metabolism by several 
workers. The clearance of paracetamol is higher in subjects 
exposed to enzyme-inducing agents such as cigarette smoking 
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and alcohol (Mucklow et al, 1980), oral contraceptive 
steroids (Mitchell et al, 1983; Mucklow et al, 1980; Miners, 
Attwood & Birkett, 1983), diet containing charcoal-grilled 
beef (Anderson et al, 1983), phenytoin, carbamazepine and 
sulphinpyrazone (Miners, Attwood & Birkett, 1984b). 
Enzymatic activity may be reduced in liver disease. Reduced 
clearance of paracetamol was observed in patients with 
severe liver disease (Forrest et al, 1979) and Gilbert's 
syndrome (Douglas, Savage & Rawlins, 1978). Antipyrine, 
another low extraction ratio drug, also has reduced 
clearance in severe liver disease (Farrell et al, 1978). 
Posture does not appear to cause any changes in liver enzyme 
activity, although Elfstrom & Lindgren (1978) reported 
increased clearance of phenazone (antipyrine) when subjects 
were supine. The increase was small and was attributed to 
the small effect increased blood flow would have on a low 
extraction ratio drug rather than change of enzyme activity. 
1.2.4: FACTORS AFFECTING RENAL ELIMINATION 
The kidney is a very important organ of drug elimination for 
both parent drug and its metabolites. All drugs in the 
systemic circulation are filtered at the glomerulus but the 
renal clearance of a drug depends on the balance between its 
glomerular filtration, active tubular secretion and passive 
reabsorption. 
At the glomerulus, only non protein bound drug is filtered, 
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so, depending on whether the drug is reabsorbed or not, any 
of the conditions that modify drug protein binding (section 
1.2.2) will alter the rate of drug clearance. This is of 
clinical importance for drugs normally highly bound to 
plasma proteins such as phenytoin, valproic acid and 
warfarin (Brater & Chennavasin, 1984). The other 
determinants of a kidney's capacity to filter drugs are the 
number of filtering nephrons and the integrity of the 
glomeruli of those nephrons. The effects of disease that 
may alter glomerular function on pharmacokinetics have been 
reviewed recently by Brater & Chennavasin (1984) and 
Gambertoglio (1984). 
Although changes in renal blood flow may affect the active 
secretion and passive reabsorption of drugs, these will only 
be of importance for drugs of high renal extraction ratio. 
The glomerular filtration rate does not alter significantly 
with changes in renal plasma flow (Knox et al, 1975). A 
number of clinically important drugs undergo active 
secretion. These have been listed by Brater & Chennavasin 
(1984) and include the penicillins, nitrofurantoin, 
thiazides and many non-steroidal antiinflammatory agents 
amongst the acids and cimetidine, amiloride, triamterene, 
pethidine and amantadine amongst the bases. 
Renal blood flow is affected by posture, exercise and 
stress. Brun, Knudsen & Raaschou (1945) observed a fall in 
kidney blood flow of 20 - 45% when subjects moved from a 
supine to an upright position. In a comparison of renal 
blood flow during bedrest and during various grades of 
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exercise while upright, Chapman et al (1948) observed a 
decline in renal blood flow of 15 - 35% depending on the 
level of exercise. Radigan & Robinson (1949) also observed 
a substantial drop in kidney blood flow with exercise and an 
even greater fall during exercise under heat stress. In 
that study, glomerular filtration rate was unaffected by 
exercise in ambient temperatures but decreased under heat 
conditions. Breiby et al (1983) found no change in kidney 
blood flow when subjects moved from a supine position to a 
sitting position. The penicillins are high renal extraction 
ratio drugs and Levy (1967) attributed the higher benzyl-
penicillin levels in ambulant compared to bedrested 
subjects, observed by Schmidt & Roholt (1966), to a 
decreased renal clearance associated with a reduced renal 
blood flow. Roberts & Denton (1980) found a similarly 
reduced renal clearance of amoxycillin in ambulant subjects 
compared to supine and sleeping subjects. That changes in 
renal plasma flow may be responsible for these results is 
possibly confirmed by the study of Breiby et al (1983) where 
sitting caused no change in either renal blood flow or the 
clearance of ampicillin. Exercise has been found to reduce 
the renal clearance of atenolol (Mason et al, 1980), 
pralidoxime and para-aminohippurate (Swartz & Sidell, 1973). 
The reabsorption of weak acids and weak bases will depend on 
their physico-chemical properties, the pH of the distal 
tubular urine and the urine flow. Diet, drugs and the 
condition of the patient can influence urinary pH. The 
elimination of several sulphonamides (Dettli, 1973; Vree et 
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al, 1978b), amphetamine (Beckett & Rowland, 1964) and 
tetracycline (Jaffe et al, 1973) have been found to vary 
with urine pH or urine flow. Sleep produces an acidosis 
which is reflected in the urine (Elliott, Sharp & Lewis, 
1959) while in bedrested patients urinary pH is higher than 
in ambulant or sleeping subjects (Roberts & Denton, 1980) 
1.2.5: CIRCADIAN RHYTHMS 
Most body functions exhibit circadian rhythms and many of 
these (e.g. cardiac output, gastrointestinal motility, 
urinary and gastric pH, liver and renal blood flow) may 
influence the absorption and disposition of drugs. Studies 
showing these circadian effects on the pharmacokinetics of 
drugs have been extensively reviewed (Ritschel, 1984; 
Reinberg & Smolensky, 1982; Levy, 1982). As some of the 
pharmacokinetic changes have been associated with diurnal 
rhythms, the effects of posture have not always been 
separated from the effects of a true rhythm. An example is 
the disposition of theophylline. A diurnal rhythm in 
theophylline plasma levels following an oral dose of 
sustained-release theophylline was described by Smolensky et 
al (1982). Taylor et al (1983) reported a diurnal rhythm in 
theophylline absorption. A recent study, however, has shown 
that the diurnal variation in theophylline levels can be 
explained, at least in part, by differences in posture 
(Warren et al, 1985). These findings highlight the need to 
take posture into account when describing the 
pharmacokinetics of a drug. 
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CHAPTER 2 
AIMS 
Posture has been shown to affect the pharmacokinetics of 
. many drugs and some reports of diurnal rhythms in drug 
disposition may, in fact, be due to changes in posture. The 
aims, therefore, of this study were to examine , in a 
systematic manner, the effects of posture on the 
pharmacokinetics of a number of selected drugs and for those 
drugs, separate the effect of sleep from the effects of 
posture. 
The drugs were chosen on the basis of their disposition 
characteristics and their clinical importance. The 
following drugs were studied: gentamicin, benzylpenicillin, 
sulphamethoxazole, trimethoprim, and paracetamol. 
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CHAPTER 3 
GENTAMICIN 
3.1: INTRODUCTION 
3.1.1: DRUG PROFILE 
Gentamicin is an effective and widely used bactericidal 
antibiotic, particularly useful in the treatment of serious 
gram-negative bacterial infections. The clinically 
available form of gentamicin is a complex consisting of 
three major components (gentamicins C1,Cla and C 2 ) and 
several minor components (Wilson, Richard & Hughes, 1973a; 
Anhalt, Sancilio & McCorkle, 1978). In commercial batches 
of the drug, there are wide variations in the relative 
proportions of these components (Anhalt et al, 1978; Wilson 
et al, 1973a) and the United States Pharmacopeia (1984) is 
the only official monograph which sets limits on the 
relative amount of each component allowed in the complex. 
Little attention appears to have been paid to the in vivo  
antibacterial potency of the different components. In vitro  
studies of the susceptibilities of various microorganisms to 
the individual components (C 1 , C ia , C 2 ) have indicated a 
range of minimum inhibitory concentration ratios (Waitz & 
Weinstein, 1969). 
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A limitation on the use of gentamicin is its narrow 
therapeutic index, with high peak concentrations being 
associated with ototoxicity and high trough concentrations 
appearing to increase the risk of nephrotoxicity (Evans et 
al, 1980). There may be differences in toxicity between the 
major components. Mosegaard, Welling & Madsen (1975) 
suggested that the use of gentamicin complex may result in a 
greater incidence of renal function impairment than the use 
of gentamicin C 1 alone. More recently, Kohlhepp et al 
(1984) compared the nephrotoxicity in rats of gentamicin 
complex with that of its major components. They found the 
nephrotoxicity of gentamicin complex to be due largely to 
the C 2 component with gentamicin C la being much less 
nephrotoxic and gentamicin C 1 producing minimal 
nephrotoxicity. So far, dosing regimes do not take into 
account either differences in component content of the 
product or differences in the pharmacology of the 
components. 
In attempts to overcome the potential toxicity problems, 
several dosing nomograms have been developed which take into 
account many patient factors including renal function, sex, 
and lean body weight (Schumacher, 1975; Barza & Lauermann, 
1978; Korsager, 1980). In spite of these nomograms, there 
is still large intersubject variability in serum 
concentrations of gentamicin following a calculated dose 
(Kaye, Levison & Labovitz, 1974; Fischer, Hedrick & Riff, 
1984). None of the nomograms take into account the posture 
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of the patient. 
3.1.2: ASSAYS 
Several assay methods are available for monitoring 
gentamicin in biological fluids in the clinical setting. 
Traditionally, microbiological assay has been the most 
common assay technique used but this method is slow, often 
inaccurate and subject to interference by other antibiotics 
(Reeves & Bywater, 1975). Recently a number of new assay 
methods have been published that are faster, more specific 
and more accurate. These methods include radioimmunoassay, 
fluorescent immunoassay, enzyme immunoassay and the 
adenylation methods (Ratcliff et al, 1981; Matzke et al, 
1982). The immunoassay methods utilize the principle of 
competitive binding and are supplied in kit form containing 
all the necessary reagents and antibiotic standards. A 
batch of five samples can be assayed, using these or the 
adenylation assays, in less than two hours, with the enzyme 
immunbassay taking as little as twenty minutes (Ratcliff et 
al, 1981). The methods have been compared by several 
authors (Matzke et al, 1980; Ratcliff et al, 1981; Hospes, 
Boskma & Brouwers, 1982; Matzke et al, 1982; Rotschafer et 
al, 1983). Matzke et al (1980) found that although the 
results of the assay techniques correlated well with the 
expected values, a given value from one assay may not be 
reproducible when the sample is assayed by a different 
technique and that intra-assay variations of ±24-31% may be 
experienced. Rotschafer et al (1983) found assay-dependent 
differences in calculated pharmacokinetic parameters which 
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resulted in markedly different dosage recommendations. 
These assays do not include a chromatography step prior to 
analysis and hence the individual gentamicin components (C 1 , 
C la and C 2 ) are quantified as a combined amount. 
Wilson et al (1973a) quantified the individual components of 
gentamicin using combined thin-layer chromatography and 
microbiology techniques. High-performance liquid 
chromatography (HPLC) equipment is becoming more common in 
laboratories and a number of HPLC assays for gentamicin in 
biological fluids have been developed (Peng et al, 1977; 
Maitra et al, 1977; Anhalt, 1977; Anhalt & Brown, 1978; 
Back,Nilsson-Ehle,Nilsson-Ehle, 1979; Larsen, Marinelli & 
Heilesen, 1980; Walker & Coates, 1981; Barends, Zwaan & 
Hulshoff, 1981; Marple & Oates, 1982; Kabra, Bhatnagar & 
Nelson, 1983; Essers, 1984). However, few HPLC assays 
separate the individual gentamicin components and of those 
that do, some of the methods are limited by the requirement 
for post-column derivatisation (Anhalt, 1977; Anhalt & 
Brown, 1978), the use of unsuitable mobile phases (Maitra et 
al, 1977; Back et al, 1979) or the use of sophisticated 
automation equipment (Essers, 1984). 
3.1.3: PHARMACOKINETICS 
Gentamicin is a highly polar compound and is not absorbed 
from the gastrointestinal tract, hence, administration is 
either intramuscular or intravenous. The disposition of 
gentamicin has been described by one-compartment, two- 
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compartment and three-compartment models. Although many 
authors consider the one-compartment model sufficiently 
accurate to use in the design of dosage nomograms (Hull & 
Sarubbi, 1976; Korsager, 1980; Bauer et al, 1983; Berg et 
al, 1983), other workers claim that a minimum of two 
compartments are necessary to adequately describe gentamicin 
disposition (Evans et al, 1980; Schentag et al, 1977). 
Following administration, gentamicin rapidly distributes 
into extracellular fluid but peripheral distribution into 
certain tissues (especially the kidney) is much slower and 
accumulation in those tissues may continue for several days 
on multiple dosing (Schentag et al, 1977). The initial 
distribution of gentamicin is related to the lean body mass 
of the subject and gentamicin has been found to have an 
apparent volume of distribution of approximately 0.24 1/kg 
(ideal body weight) (Gyielynck, Forrey & Cutler, 1971; Hull 
& Sarubbi, 1976) although for obese patients, some authors 
add a correction factor to account for small but significant 
distribution into the adipose tissue (Korsager, 1980; Bauer 
et al, 1983). The reported protein binding of gentamicin 
has ranged from 0 to 30% but it appears that binding to 
plasma proteins is negligible (Pechere & Dugal, 1979). 
Gentamicin is not metabolised but is eliminated solely by 
the kidney (Schentag et al, 1977). The major route of 
elimination is by glomerular filtration although there is 
evidence that some tubular reabsorption occurs (Schentag et 
al, 1977). Thus, it is considered to have a low renal 
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extraction ratio. 
The pharmacokinetics of the individual gentamicin components 
have never been fully described. Nation et al (1978) 
compared gentamicin C 1 with gentamicin (C ia ,C 2 ) levels in 
patients. However, the components C ia and C 2 were not 
resolved in that study and the evaluation was restricted to 
the analysis of gentamicin in a limited number of blood 
samples collected at random from patients. Based on this 
limited evaluation, Nation et al (1978) concluded that the 
disposition of all three components of the gentamicin 
complex is the same or very similar. Mosegaard et al (1975) 
had previously suggested that substantial differences may 
exist between the pharmacokinetics of gentamicin complex and 
gentamicin C l . Differences in both the volume of 
distribution and serum clearance of gentamicin and 
gentamicin C 1 were reported. 
In the present studies, the effects of posture and sleep on 
the disposition of gentamicin complex and the individual 
components were examined. The effects of sex and menstrual 
cycle on gentamicin pharmacokinetics were also studied. 
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3.2: ANALYSIS 
3.2.1: MATERIALS AND METHODS 
Gentamicin sulphate containing 563 mg gentamicin base per 
milligram of powder with a component ratio of C 1 25.4%, C ia 
31.7%, C 2 42.9%, was supplied by Essex Laboratories, Sydney, 
Australia. All solvents were specially purified to HPLC 
grade. Water was de-ionised and glass distilled daily. All 
other chemicals were reagent grade. O-phthalaldehyde 
reagent was prepared according to the method of Maitra et al 
(1977). 
3.2.1.1: Chromatographic equipment 
Separation was performed using a Waters M6000A solvent 
delivery system fitted with a U6K injector. A C 18 pBondapak 
column (particle size lOpm; 300 mm x 3.9 mm I.D.;Waters 
Associates, Milford, MA, USA) was used in combination with a 
guard column (pBondapak C 18 /Porasil B; Waters Associates; 23 
mm x 3.9 mm I.D.). Detection of fluorescent products in the 
eluent was performed using a Schoeffel model FS970LC 
fluorometer (Schoeffel Instrument Corp, Westwood, NJ, USA) 
with fluorescence excitation at 260 nm and emission 
detection at 418 nm. Detector signal was recorded on a 
dual-channel Omniscribe recorder (Houston Instruments, 
Austin, TX, USA).. The mobile phase was 1% triethylamine 
(TEA) ,solution (adjusted to pH6.2 ± 0.1 with phosphoric 
acid) - methanol (79:21) mixture. The flow rate was 2 
ml/min. Injections were made with a 25 pl Hamilton Syringe. 
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3.2.1.2: Sample preparation 
Preparation of derivatised gentamicin from serum samples was 
performed by the method of Maitra et al (1977) with some 
modification. In this method a disposable Pasteur pipette 
was plugged with silanized glass wool and about 150 mg of 
dry silicic acid was added to form a silicic acid column of 
1.0 cm height. The column was treated with 1.0 ml of water. 
Serum (0.5 ml) was diluted to 2.0 ml with water, vortexed,•
and applied to the silicic acid column. The serum sample 
tube was rinsed with 1.0 ml water which was then applied to 
the column and eluted with the help of pressure from a 
rubber bulb. The eluate was discarded. Immediately o-
phthalaldehyde reagent (0.5m1) was applied to the column and 
allowed to stand for 30 seconds. The reagent was eluted 
with the aid of pressure from the rubber bulb and the eluate 
was discarded. The derivatised gentamicin was then eluted 
from the column by adding 1.5ml of methanol. The eluent was 
vortexed, centrifuged and stored in the dark until injected. 
20p1 of tha sample was injected onto the column. 
3.2.1.3: Preparation of standard curves 
Plasma standards were prepared by spiking drug-free plasma 
with known amounts of a freshly-prepared aqueous solution of 
gentamicin to produce concentrations of 1-20 mg/1 total 
gentamicin (representing 0.14 - 2.86 mg/1 C l , 0.18 - 3.57 
mg/1 C ia , 0.24 - 4.83 mg/1 C 2 ). 
The standards were then assayed in the described manner. 
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Standard curves were prepared by plotting the peak heights 
of the components versus concentration. 
3.2.2: RESULTS 
Chromatograms of blank serum and serum from a subject 
following intravenous administration of gentamicin are shown 
in Figure 3.1. The three major gentamicin components were 
well separated from each other and eluted in the order of 
C 	C la and C 2 at 4.8, 6.8 and 8.6 minutes, respectively. 
Peak heights and serum concentrations were linearly related 
for each of the three components over the concentration 
range used for the standard curves (r>0.99) (Figure 3.2). 
The intra- and inter-day reproducibility of the assay are 
shown in Table 3.1. 
3.2.3: DISCUSSION 
At the time of this study, the only HPLC methods capable of 
separating the major gentamicin components were those of 
Anhalt (1977), Maitra et al (1977) and Back et al (1979). 
The method of Anhalt (1977) used post-column derivatisation 
which, although reliable, has some disadvantages including 
the need for additional pumping equipment and a mixing 
chamber (not available in this laboratory); a high 
consumption of reagent; and an increase in baseline noise 
due to the pumping of derivatising agent through the 
detector (Essers, 1984). Pre-column derivatisation is 
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Figure 3.1 Chromatograms of (a) blank serum and (b) serum 
from the same subject 80 minutes after intravenous 
administration of lmg/kg lean body weight dose of 
gentamicin. The gentamicin concentration is estimated to be 
0.38 mg/1 (C 1 ), 0.57 mg/1 (C ia ) and 0.45 mg/1 (C 2 ) 
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Figure 3.2 Standard curves for gentamicins C 	C la and C 2' 
The concentration axis represents the concentration of total 
standard powder per millilitre of serum. The actual 
concentrations are given in the table below. 
Concentration (mg/1) 
Total sample 1 C la C 2 
5 0.715 0.893 1.208 
10 1.430 1.785 2.415 
15 2.145 2.677 3.623 
20 2.860 3.570 4.830 
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Table 3.1 Intra- and inter-day variation of gentamicin 
in serum 
Concentration 
(mg/1) 
CV 
1 
(%) of component 
C la 2 
2 
10 
Intra-day 
Inter-day 
Intra-day 
Inter-day 
(n=5) 
(n=6) 
(n=5) 
(n=10) 
6.76 
8.87 
6.05 
6.49 
11.66 
19.76 
5.13 
7.22 
7.02 
14.82 
6.36 
10.35 
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simpler, requiring no additional machinery and is likely to 
eliminate more interfering material (Maitra et al, 1979). 
The methods of 'Maitra et al (1977) and Back et al (1979) use 
pre-column derivatisation and are identical except in the 
manner of sample extraction. Back et al (1979) modified the 
method of sample extraction to allow the assay of several 
aminoglycosides by the same technique. In the method of 
Maitra et al (1977) the derivatising agent, o-phthal-
aldehyde, is included in the eluent subsequently injected 
onto the column. However, during the development of the 
present assay, the inclusion of this reagent led to a 
decrease in sample peak height throughout the day. As the 
o-phthalaldehyde reagent is alkaline (pH 10.4), its repeated 
injection may have destroyed the silica skeleton of the 
stationary phase of the pre-column and column. It was found 
that this problem was overcome by discarding the 
derivatising eluate, then eluting the derivatised gentamicin 
with methanol. To assess that this method still provided 
satisfactory recovery, comparison was made of samples 
containing 0.1 ml of drug solution, 0.5 ml o-phthalaldehyde 
reagent and 0.9 ml methanol (total volume 1.5 ml), vortexed, 
centrifuged then injected onto the column, with samples 
prepared as described (1.5 ml methanol eluent). This 
comparison showed that the peak heights were higher when the 
reagent was not included. In the automated method of Essers 
(1984), the problem was overcome by pre-saturating the 
derivatising solution with silica. 
Maitra et al (1977) used excitation and emission wavelengths 
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of 340 nm and 418 nm, respectively. In this study it was 
found that these wavelengths resulted in an unacceptably low 
peak height : noise ratio. Excitation at 260 nm and 
emission at 418 nm provided negligible background noise and 
good sensitivity, giving optimal peak height : noise ratios. 
In the development of this assay, the mobile phase of Maitra 
et al (1977) of EDTA-methanol was used initially and this 
provided good resolution with retention times (C 1, 5.6 min; 
C la 7.2 min; C 2' 9.6 min) similar to those of the published 
method (C 1 4.7 min, C la 7.2 min, C 2 9.5 min). However, 
continued use of this mobile phase over a few days led to 
loss of peak resolution. This was restored by either 
increasing the water content of the mobile phase with 
associated longer retention times or increasing the EDTA 
concentration. The pH of the mobile phase (pH 8.75) was 
higher than the top of the optimum pH range (pH 2 - 7) for 
bonded-phase silica-based column packings (Giese, 1983). At 
this pH the silica matrix is likely to dissolve and release 
of bonded groups from the surface may occur. These factors 
may account for the loss of resolution experienced in this 
study. A change from EDTA to 1% triethylamine (TEA) 
adjusted to pH 6.2 ± 0.1 with phosphoric acid gave 
resolution similar to that initially experienced using the 
EDTA-methanol mobile phase. This mobile phase provided 
stable chromatograms over several weeks with the same column 
and injection of hundreds of samples. Comparison of 
chromatograms using EDTA-methanol and using TEA-methanol 
show similar resolution and sequence of elution of the 
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Figure 3.3 Chromatograms of serum spiked with C 1 
(1.43mg/1), Cla  (1.785mg/1) and C 2 (2.415mg/1) and assayed 
(a) using the mobile phase of Maitra et al (1977) containing 
EDTA and (b) the mobile phase of the present method 
containing triethylamine (TEA) 
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Components (Figure 3.4). 
This method provides a simple, rapid assay for the deter-
mination of the three major components of gentamicin (C 1 , 
C la and C 2 ) with sufficient sensitivity for use in clinical 
and pharmacokinetic studies. 
3.3: PRARMACOKINETIC STUDY 
3.3.1: CLINICAL PROTOCOL 
3.3.1.1: Subjects 
Twelve healthy, young adult volunteers (six male, six 
female) aged 21 to 29 years participated in the study. 
Prior to the investigation, a detailed medical history was 
taken. No subjects gave a history of liver or renal 
disease. Physical examination, haematological tests and 
liver and renal function tests for all subjects were normal. 
Informed consent was obtained from each subject; approval 
was obtained, before commencing the study, from the Human 
Ethics Committee of the University of Tasmania. 
3.3.1.2: Procedure 
Each subject was assessed for lean body mass by measurement 
of skin fold thickness at four sites (Durnin & Womersley, 
1974). Gentamicin (1 mg/kg lean body mass) (Essex 
Laboratories, Sydney, Australia) was administered by slow 
intravenous bolus (over 3 minutes) to each subject on three 
separate occasions - during bedrest in the day, immediately 
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prior to sleep at night (usually at midnight) and during 
daytime ambulation. One subject (ABI) did not participate 
in the sleep study. To assess the effects of menstrual 
cycle on gentamicin disposition, four of the female subjects 
were administered the dose on a second occasion of daytime 
bedrest. Changes in posture were not allowed throughout 
each section of the study. At least two weeks elapsed 
between each section of the study. 
3.3.1.3: Sample collection 
An indwelling catheter was inserted into the antecubetal 
vein of the arm not used for dosing, approximately one hour 
before dosing. Patency of the catheter was maintained by 
flushing with a small volume of heparinised saline (10 
IU/ml) after each blood sample was withdrawn. Subjects then 
adopted the posture required for the study. 5 ml blood 
samples were withdrawn at 0, 3, 15, 30, 45, 60, 80, 100, 
120, 180, 240, 300, 360 and 480 minutes. To avoid possible 
interaction between gentamicin and heparin (Myers et al, 
1978), the first 1.0 ml of blood was drawn separately and 
discarded then the samples were collected into non-
heparinised tubes and allowed to clot at room temperature 
before being centrifuged. The serum was drawn off using 
sterile Pasteur pipettes and stored at -20°C until assayed. 
3.3.1.4: Pharmadokinetics and statistics 
The serum total gentamicin concentration (C) versus time (t) 
data were fitted to a biexponential equation of the 
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following form 
C = Ae -at  + Be 	(3.1) 
corresponding to a 2-compartment model by non-linear 
regression analysis. The calculated values of A, B, a, 8 
were used to estimate the half-life of the a phase (t, ) and la 
of the 	phase (t 1/2 ), the area under the curve (AUC), the 
body clearance (CL B ), the apparent volume of distribution 
(V) and its components, the apparent volumes of the central 
compartment (Vc ) and tissue compartment (VT ) (Gibaldi & 
Perrier, 1982a). 
In addition, the disposition of total gentamicin and the 
individual gentamicin components (C1, Cla' C 2 ) was 
characterised by non-compartmental methods using statistical 
moment theory. The terminal elimination rate constant (8) 
was determined from the slope of the terminal linear segment 
of a semilogarithmic plot of serum concentration versus 
time. The zero moment of the drug concentration-time curve, 
the area under the curve (AUC), was calculated according to 
trapezoidal rule from concentration-time data following drug 
administration (Gibaldi and Perrier, 1982b). The first 
moment, the mean residence time (MRT), was calculated 
according to Equation 3.2 (Gibaldi and Perrier, 1982b). 
MRT = 
AUMC 	 ortCdt 
AUC orCdt 
(3.2) 
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The apparent total serum clearance (CL B ) was calculated by 
dividing the dose of the component (D iv ) by the area under 
the curve (AUC). The volume of distribution at steady-state 
(VSS ) for each component and total gentamicin was calculated 
from Equation 3.3 (Gibaldi and Perrier, 1982b) 
D. .AUMC 
Iv  V 	= CLB .MRT = 	 (3.3) ss 
The elimination half-life (t 113 ) was also calculated for each 
of the gentamicin components in the usual manner (t 1 = 
0.693/8). 
Urine flow was the mean value observed during the first 
eight hours after dosing. 
Statistical comparisons of the pharmacokinetic parameters 
for total gentamicin and the gentamicin components were made 
by one-factor analysis of variance with repeated measures 
(Ferguson, 1976). Statistical comparison of the effect of 
sex and stage of menstrual cycle on the disposition of 
gentamicin was made by one-way analysis of variance or t-
test, as appropriate (Ferguson, 1976). 
3.3.2: RESULTS 
The mean serum total gentamicin levels versus time profiles 
during ambulation, bedrest and sleep are presented in Figure 
3.5. The mean concentration-time curve for ambulant 
AUC 2 
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subjects was lower at all times than the curves for sleep 
and bedrest. The individual experimental and 
pharmacokinetic data for gentamicin in subjects during 
ambulation and sleep are shown in Tables 3.2 and 3.3, 
respectively. The data for male and female subjects during 
bedrest are shown in Tables 3.4 and 3.5, respectively. The 
mean experimental and pharmacokinetic data for total 
gentamicin derived from individual concentration-time curves 
are shown in Table 3.6. 
Pharmacokinetic analysis of total gentamicin according to a 
two-compartment model showed significant differences between 
ambulation and supine (bedrest and sleep) values for all the 
parameters determined except total body clearance. In each 
case the values of the parameters obtained during bedrest 
did not differ significantly from those obtained during 
sleep. Non-compartmental analysis based on statistical 
moment theory showed statistically significant differences 
between the values determined for ambulant subjects and 
those for supine subjects (bedrest and sleep) for the area 
under the curve (AUC), volume at steady state (V ss ) and 
total body clearance (CLB ). 
Figure 3.6 shows the concentration-time curves for each of 
the major gentamicin components during ambulation, sleep and 
bedrest. Again, at all times the gentamicin component 
concentrations during ambulation were lower than during 
bedrest and sleep. The mean pharmacokinetic data determined 
38 
1'1 
se
ru
m
  g
en
ta
m
ic
in
  
60 	120 	180 	240 	300 	360 
time (min) 
Figure 3.4 Mean (±SD) serum total gentamicin concentrations 
found in healthy adult volunteers following administration 
of a lmg/kg (lean body mass) dose of gentamicin during 
A ambulation, 	0 bedrest and 0 sleep 
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Table 3.2 Experimental and pharmacokinetic data describing the disposition of gentamicin in ambulatory subjects 
Parameter a 	 Subjects 
PT 	CH 	MP 	MR 	BP 	RL 	CF 	FW 	JR 	AB 	MH 	ABI 
Age (y) , 	22 	21 	21 	22 	21 	21 	21 	23 	22 	21 	21 	29 
Sex M 	M 	M 	M 	M 	M 	F 	F 	F 	F 	F 	F 
TBW (kg) 	71.8 	67.5 	69.0 	61.3 	72.1 	63.3 	58.1 	62.1 	60.5 	60.9 	65.6 	61.6 
LBM (kg) 63.3 	57.6 	61.3 	55.2 	64.7 	57.7 	41.5 	43.8 	44.0 	39.5 	46.2 	46.2 
AUC (min.mg/1) 	402 	740 	507 	1140 	802 	830 	543 	658 	455 	562 	877 	814 
t, 	(min) 	17.33 	115.69 	29.75 	62.75 	20.19 	61.94 	18.47 	5.80 	10.96 	13.79 	49.98 	56.04 la 
t 	(min) 118.7 	564.9 	159.7 	693.0 	185.5 	427.1 	137.2 	178.3 	119.8 	140.8 	724.2 	884.7 1/28 
✓ (1/kg TBW) 	0.376 	0.940 	0.404 	0.790 	0.299 	0.677 	0.260 	0.276 	0.276 	0.235 	0.839 	1.176 
✓ (1/kg LBM) 0.426 	1.101 	0.455 	0.877 	0.334 	0.742 	0.365 	0.391 	0.380 	0.362 	1.191 	1.569 
CL
B
b (ml/min) 	157.51 	77.81 	121.00 	48.40 	80.64 	69.51 	76.42 	66.54 	96.77 	70.34 	52.66 	56.77 
✓ LBM) 	0.336 	0.579 	0.356 	0.590 	0.242 	0.507 	0.312 	0.359 	0.330 	0.319 	0.862 	0.471 
MRT (min) 	141.5 	515.3 	188.1 	690.8 	198.0 	438.1 	172.5 	262.1 	155.9 	183.7 	748.6 	205.3 
CL
B
c (ml/min) 	150.22 	64.75 	116.08 	47.16 	79.03 	66.80 	75.04 	59.93 	93.22 	68.52 	53.18 	106.01 
Urine flow (ml/min) 	0.54 - 	0.54 	0.15 	0.62 	0.52 	0.66 	0.54 	0.62 	1.25 	1.39 	0.57 	3.60 
a TBW - total body weight; LBM - lean body mass; AUC - area under the serum-concentration-time curve; t 	- distribution half- 
life; t 	elimination half - life; V - volume of distribution; CL B - total body clearance; V ss - volume of distribution 
at steady-state; MRT - mean residence time 
b CL - total body clearance calculated using the AUC estimated in the compartmental pharmacokinetic analysis. 
c CL 8 - total body clearance calculated using the AUC estimated by the trapezoidal rule. 
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Table 3.3 	Experimental and pharmacokinetic data describing the disposition of gentamicin in sleeping subjects 
Parametera 
PT CH MP MR BP 
Subjects 
RL 	CF FW JR AB MM ABI 
Age 	(y) 22 21 21 22 21 21 21 23 22 21 21 29 
Sex m M M M M M F F F F F F 
TBW 	(kg) 71.8 67.5 69.0 61.3 72.1 63.3 58.1 62.1 60.5 60.9 65.6 61.6 
LBM 	(kg) 63.3 57.6 61.3 55.2 64.7 57.7 41.5 43.8 44.0 39.5 46.2 46.2 
AUC 	(min.mg/1) 1014 885 837 638 944 1161 549 626 628 727 664 
t
15a 
(min) 13.89 17.37 21.46 15.24 18.39 12.46 67.12 17.95 9.99 29.95 2.71 
(min) t
1/2B 
160.9 159.3 143.7 117.4 171.2 153.4 118.4 168.0 112.9 155.4 154.4 
V 	(1/kg TBW) 0.201 0.222 0.220 0.239 0.235 0.174 0.222 0.273 0.189 0.200 0.236 
V 	(1/kg LBM) 0.236 0.260 0.248 0.266 0.262 0.191 0.311 0.387 0.259 0.308 0.335 
CL
B
b (ml/min) 62.40 65.07 73.24 86.58 68.50 49.68 75.59 70.02 70.06 54.31 69.55 
V 	LBM) 0.187 0.249 0.212 0.240 0.223 0.204 0.303 0.344 0.216 0.238 0.269 
MRT 	(min) 	' 192.7 240.2 180.1 153.3 214.6 223.0 171.1 220.2 136.4 175.0 192.5 
CL
B
c 	(ml/min) 61.46 59.80 72.05 86.48 67.14 52.75 73.51 68.37 , 69.72 53.61 64.47 
Urine flow (ml/min) 1.34 - 1.20 0.60 1.43 0.77 1.96 1.01 0.65 1.20 1.16 1.01 
a Parameters as defined in Table 3.2 
CL B - total body clearance calculated using the AUC estimated in the compartmental pharmacokinetic analysis 
CL B - total body clearance calculated using the AUC estimated by the trapezoidal rule 
Table 3.4 Experimental and pharmacokinetic data describing the 
disposition of gentamicin in male subjects during bedrest 
Parametera PT CH 
Subject 
MP MR BP RL 
Age 	(y) 22 21 21 22 21 21 
TOW (kg) 71.8 67.5 69.0 61.3 72.1 63.3 
LBM (kg) 63.3 57.6 61.3 55.2 64.7 57.7 
AUC 	(min.mg/1) . 742 829 748 837 1294 868 
t Lia 	(min) 5.70 9.17 20.47 7.11 38.00 38.94 
t
10 
(min) 142.4 139.3 102.2 87.2 263.1 280.4 
V (1/kg TBW) 0.244 0.207 0.175 0.135 0.263 0.425 
V (1/kg LBM) 0.277 0.243 0.197 0.150 0.293 0.466 
CLB
b (ml/min) 85.27 69.50 81.93 65.92 49.98 66.44 
V 	(1/kg LBM) ss 0.238 0.218 0.156 0.140 0.163 0.290 
MRT (min) 184.8 187.6 124.1 124.4 166.7 257.8 
CLBc 	(ml/min) 81.37 66.77 77.00 62.13 63.25 64.82 
Urine flow (ml/min) 1.74 1.41 1.91 1.96 0.93 1.15 
a Parameters as defined in Table 3.2 
cLB - total body clearance calculated using the AUC estimated in the 
compartmental pharmacokinetic analysis 
CLB - total body clearance calculated using the AUC estimated by the 
trapezoidal rule 
Table 3.5 Experimental and pharmacokinetic data describing the disposition of gentamicin 
in female subjects during bedrest 
Parametera 	 Subject 
CF All FW JR AB MH 
Age 	(y) 
-TBW (kg) 
LBM (kg) 
21 
58.1 
41.5 
29 
61.6 
46.2 
23 
62.1 
43.8 
22 
60.5 
44.0 
21 
60.9 
39.5 
21 
65.6 
46.2 
Day of MC b N/A N/A 6 20 11 25 5 19 13 27 
AUC 	(min.mg/1) 432 583 991 517 603 761 801 811 824 357 
t15o 	(min) 11.37 7.75 15.67 23.90 16.98 4.42 24.80 6.86 12.78 27.57 
t 118 	(min) 66.8 139.5 153.0 132.9 80.4 159.4 129.2 151.8 214.7 73.6 
V(1/kg TBW) 0.160 0.259 0.157 0.262 0.140 0.220 0.151 0.175 0.265 0.209 
V(1/kg LBM) 0.224 0.345 0.223 0.371 0.192 0.302 0.233 0.270 0.376 0.297 
CLB c  (ml/min) 96.00 79.20 44.20 84.79 72.98 57.78 49.29 48.70 56.10 129.39 
Vss 	(1/kg LBM) 0.215 0.348 0.206 0.343 . 0.166 0.250 0.193 0.234 0.292 0.373 
MRT (min) 97.5 203.2 206.9 175.2 107.7 194.4 166.1 195.9 243.7 159.1 
CLB
d (ml/min) 91.32 79.21 43.64 85.82 67.87 56.55 45.79 47.10 55.40 108.19 
Urine flow (ml/min) 1.12 1.15 3.58 2.96 3.21 2.23 1.30 2.92 2.51 2.76 
a Parameters as defined in Table 3.2 
• Day of MC - day of menstrual cycle 
• CLB - total body clearance calculated using the AUC estimated in the compartmental pharmacokinetic analysis 
• CLB - total body clearance calculated using the AUC estimated by the trapezoidal rule 
gentamicin from data in Tables 	3.2, 3.3, 	3.4 	and 	3.5 
Parametera Ambulation 
(n 	= 	12) 
Sleep 
(n 	= 	11) 
Bedrest 
(n 	= 	12) 
TBW (kg) 64.48 ± 	4.64 64.75 ± 4.78 64.48 ± 	4.64 
LBM (kg) 51.75 ± 	9.11 52.25 ± 	9.38 51.75 ± 	9.11 
AUC (min.mg/1) 649 ± 213 788 ± 194 796 ± 	216 
t 1/21:i 	(min) 38.56 ± 	31.96 20.59 ± 	16.87 16.09 ± 	12.44 
t 156 	(min) 361.2 ± 	283.3 146.8 ± 	21.0 149.9 ± 	69.2 
V (1/kg TBW) 0.546 ± 	0.323 0.219 ± 	0.027 0.215 ± 	0.083 
V (1/kg LBM) 0.683 ± 	0.413 0.279 ± 0.053 0.268 ± 	0.090 
CLB
b (ml/min) 81.20 ± 	31.10 67.73 ± 	10.17 68.07 ± 	16.01 
Vss (1/kg LBM) 0.439 ± 	0.174 0.244 ± 0.046 0.219 ±0.064 
MRT (min) 325.0 ± 	217.6 190.8 ± 	31.7 172.5 ± 	51.7 
CLB
c (ml/min) 74.16 ± 	34.19 66.31 ± 9.61 66.55 ± 	14.20 
Urine flow (ml/min) 0.92 ± 	0.91 1.12 ± 	0.39 1.83 ± 	0.86 
N/S 
p<005d 
p<0.01 d 
p<0.01 ' 
p<001d 
N/S 
p<0•05d 
N/S 
p<005d 
p<0.05e 
Significant 
difference 
Table 3.6 Comparison of mean estimates (±SD) of pharmacokinetic parameters for 
a Parameters as defined in Table 3.2 
• CLB - total body clearance calculated using the AUC estimated in the compartmenta) 
analysis 
• CLB - total body clearance calculated using the AUC estimated by the trapezoidal 
rule 
• Ambulation significantly different from bedrest and sleep 
• Ambulation significantly different from bedrest but not sleep 
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for each of the components during each of the three states 
studied are shown in Table 3.7. 
For gentamicins C 1 and C la there were significant 
differences in the area under the curve, apparent volume of 
distribution at steady-state and total body clearance. For 
gentamicin C 2 the significant differences existed in the 
apparent volume of distribution and the total body 
clearance. In each case the values of the parameters for 
ambulation differed significantly from the values for sleep 
and bedrest. The values of the parameters determined for 
sleep were not significantly different from those for 
bedrest except for the values of the apparent volume of 
distribution at steady state for gentamicin C ia where the 
value for sleep was significantly greater than the value for 
bedrest. 
Statistical comparison of the values of the pharmacokinetic 
parameters obtained for the different components within each 
state studied showed no significant differences between the 
components for the apparent volume of distribution at steady 
state and the total body clearance. During ambulation and 
bedrest the mean residence time for gentamicin C 2 was 
significantly longer than the mean residence times for 
gentamicin C 1 and C la . During sleep the mean residence time 
for C 2 ' was significantly longer than the mean residence time 
for C 1 but was not significantly different from that for C la 
(Table 3.7). 
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Figure 3.5 Mean (±SD) serum concentration versus time 
	
profiles observed during A ambulation, 	0 bedrest and 
o sleep for (a) gentamicin C1 (b) gentamicin C ia and 
(c) gentamicin C2. 
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Table 3.7 Mean (±SD) pharmacokinetic data for gentamicin CI, C la and C 2 
determined during ambulation, sleep and bedrest 
Parameter a Ambulation 
(n 	= 	12) 
Sleep 
(n 	= 	11) 
Bedrest 
(n 	= 	12) 
Significant 
difference 
AUC C I 168.2 	± 	37.4 218.9 	± 	54.5 224.7 	± 	53.8 p<0.05 
(min.mg/1) C ia 219.9 	± 	48.4 315.3 	± 	76.9 303.1 	± 	63.2 p<0.01 
C 2 216.3 	± 	54.9 271.8 	± 	68.5 273.0 	± 60.7 N/S 
V ss C 1 16.47 	± 	2.52 11.90 	± 	3.19 10.54 	± 	3.19 p<0.01 
(1) C la 16.08 	± 	3.71 13.06 	± 	2.07 10.50 	± 	3.32 p<0.01 
C 2 17.58 	± 	3.19 12.45 	± 	2.07 11.24 	± 	3.31 p<0.01 
Significant 
difference N/S N/S N/S 
CLB C 1 96.1 	± 	32.6 72.6 	± 	9.5 71.2 	± 	16.1 p<0.05 
(ml/min) C la 92.9 	± 	21.4 64.8 	± 	9.6 67.6 	± 	15.9 p<0.01 
C2 80.9 	± 	26.9 63.3 	± 	12.8 63.0 	± 	14.7 p<0.05 
Significant 
difference N/S N/S N/S 
MRT C 1 179.7 	± 	34.2 167.4 	± 	51.5 154.3 	± 54.0 N/S 
(min) C la 175.2 	± 	25.2 202.9 	± 	26.9 157.7 	± 38.2 N/S 
C 2 227.9 	± 49.6 202.7 	± 	31.4 185.2 	± 	53.2 N/S 
Significant 
difference p<0.01 p<0.05 p<0.05 
a Parameters as defined in Table 3.2 
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In the comparison of males and females, it was found that 
the total body weight of males (67.5 ± 4.43 kg) was 
significantly greater than that of females (61.5 ± 2.45 kg) 
(p<0.05). Ideal body weights were also significantly 
different (males, 60.0 ± 3.71 kg; females, 43.5 ± 2.64 kg) 
(p<0.01). Figure 3.7 shows the mean (±SD) gentamicin 
component levels versus time profiles for males and for 
females at 2 different stages of their menstrual cycle. The 
pharmacokinetic parameters determined from those profiles 
are presented in Table 3.8. The clearance (CL B ) of 
gentamicin C 1 for females in the second half of their 
menstrual cycle was significantly different from that of 
females during the first half of their menstrual cycle 
(p<0.05) (Table 3.8). When the clearance of gentamicin C 1 
was corrected for lean body mass the clearance (CL B ) for 
males was significantly different from the clearance for 
females, independent of stage of menstrual cycle (Table 
3.8). There were no significant differences between the 
clearance of total gentamicin, gentamicin C la , gentamicin C 2 
for males and females. 
The volume of distribution at steady state (V ss ), adjusted 
for lean body mass, for gentamicin C ia for females in the 
second half of their menstrual cycle was significantly 
different from the V for males and from the V for ss 	 ss 
females in the first half of their menstrual cycle. There 
was no significant difference between males and females 
during the first half of their menstrual cycle for V ss  for 
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Figure 3.6 Mean (±SD) gentamicin concentrations versus time 
found in 0 males, 0 females during the follicular phase 
of their menstrual cycle, and A females during the luteal 
phase of their menstrual cycle for (a) total gentamicin, 
(b) gentamicin C 1, (c) gentamicin C la and (d) gentamicin C 2 
49 
Table 3.8 Mean (±SD) pharmacokinetic parameters for total gentamicin and the gentamicin components 
estimated for male subjects and for female subjects at two phases of their menstrual cycle 
Parametera Sexc 
Total C l 
Gentamicin 
C la C 2 
AUC M 873 	± 	87.3 250 ± 	22.3 325 ± 46.3 260 ± 	45.9 
F 1 837 	± 	146.1 232 ± 	53.7 318 ± 	54.7 286 ± 	45.7 
F2 639 	± 200.6 141 ± 	40.9
f 256 ± 83.6 223 ± 	101.4 
CLBb (ml/min) M 69.22 	± 	7.99 71.22 ± 	6.08 72.27 ± 	12.66 65.82 ± 	11.62 
1 53.18 	± 	11.05 58.39 ± 	15.55 52.95 , ± 	10.85 50.47 ± 	10.19 
F2 74.42 	± 	27.91 99.23 ± 	36.00
d 70.98 ± 28.90 76.00 ± 	38.32 
CLB
b M 1.155 	± 	0.110 1.190 ± 	0.108 1.204 ± 0.183 1.095 ± 	0.169 
(ml/min/kg LBM) F 1 1.224 	± 	0.230 1.341 ± 	0.319 1.217 ± 0.206 1.163 ± 	0.219 
F2 1.695 	± 	0.551 2.262 ± 0.703 e 1.615 ± 0.574 1.720 ± 0.786 
Vss 	(1/kg TBW) M 0.178 	± 	0.052 0.159 ± 	0.040 0.165 ± 0.039 0.173 ± 	0.052 
F 1 0.149 	± 	0.039 0.156 ± 	0.052 0.133 ± 0.022 0.159 ± 0.028 
F2 0.209 	± 	0.052 0.182 ± 	0.046 0.189 ± 0.027 0.191 ± 	0.034' 
Vss 	(1/kg LBM) M 0.201 	± 	0.058 0.180 ± 	0.047 0.186 ± 0.046 0.195 ± 	0.058 
F 1 0.214 	± 	0.054 0.224 ± 0.072 0.191 ± 0.035 0.228 ± 0.039 
F2 0.300 	± 	0.068 0.261 ± 0.063 0.271 ± 0.036
f 0.274 ± 	0.041 
t 	(min) M 169.1 	± 	82.5 120.0 ± 	52.7 130.1 ± 32.2 136.5 ± 46.0 1/28 
F 1 144.4 	± 	55.8 137.1 ± 	54.5 122.5 ± 36.8 163.4 ± 48.9 
F2 129.4 	± 1 38.2 81.0 ± 	17.1 137.7 ± 42.7 137.2 ± 	56.2 
a Parameters as defined in Table 3.2 
• Determined by statistical moment theory 
• M,- males (n=6); F 1 - females (n=4) during the follicular phase of their menstrual cycle; 
F 2 - females (n=4) during the luteal phase of their menstrual cycle 
• F 2 significantly different from F 1 but not M (p<0.05) 
e M significantly different from F 1 and F 2 (p<0.05) 
F 2 significantly different from M and F 1 (p<0.05) 
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gentamicin C la . The differences in V 	between males and ss 
females for the other gentamicin components and total 
gentamicin did not reach significance. Nor did any 
differences in V between females during the different ss 
stages of their menstrual cycles (Table 3.8). Differences 
in sex and in stage of menstrual cycle had no significant 
effect on the other parameters (MRT, t 1/2r3 ) determined for the 
gentamicin components (Table 3.8). 
3.3.3: DISCUSSION 
The values for the compartmental pharmacokinetic parameters 
for total gentamicin in this study (Table 3.6) are similar 
to those observed by several other workers following 
administration of gentamicin to subjects with normal renal 
function (Cutler et al, 1972; Kaye et al, 1974; Sawchuck et 
al, 1977; Leroy et al, 1978; Bauer & Blouin, 1983; Bauer et 
al, 1983). As found by Kaye et al (1974) and Michelson et 
al (1976), there is a wide inter-subject variation in the 
disposition kinetics for gentamicin, especially for ambulant 
subjects (Table 3.6). The non-compartmental pharmacokinetic 
parameters, mean residence time (MRT) and volume at steady 
state (V s ), have not been described by other workers. s 
The pharmacokinetics of gentamicin have been described 
previously by one-compartment, two-compartment and three-
compartment models. The inadequacy of the one-compartment 
model in providing useful parameters for dosing has been 
discussed by several workers (Wilson et al, 1973b; Evans et 
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al, 1980; Schentag et al, 1977). In examining the 
disposition of gentamicin over a normal dosing interval, a 
two-compartment model appears to adequately describe the 
pharmacokinetics of the drug. However, parameters obtained 
from a two-compartment model do not account for the slow, 
continuing rise in peak and trough levels observed on 
repeated dosing. Gentamicin appears to slowly distribute 
into tissues, particularly the kidney, saturation of the 
tissues taking several days (Schentag et al, 1977). The 
present study describes the disposition of gentamicin over a 
normal dosing interval (8 hr) during which ambulation and 
sleep could be maintained. 
The higher volume of distribution observed in ambulant 
subjects (Table 3.6) may reflect the greater perfusion of 
peripheral areas during ambulation since skeletal muscle 
blood flow may increase nearly four-fold with exercise 
(Vatner & Pagiani, 1976) with a decrease in blood flow to 
the kidney and liver (Chapman et al, 1948; Culbertson et al, 
1947; Brengelmann, 1983). Schentag et al (1977) described 
skeletal muscle as a large volume, low concentration organ 
for gentamicin distribution. A similar change in volume of 
distribution with exercise was observed for another highly 
polar, renally excreted drug, pralidoxime (Swartz & Sidell, 
1973). 
The total clearance determined by compartmental analysis did 
not show any significant difference between the different 
states examined although the mean clearance during 
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ambulation was greater than the clearance in either supine 
state. In the non-compartmental pharmacokinetic analysis, 
the total body clearance of gentamicin in ambulant subjects 
was significantly greater than in supine subjects (Table 
3.6). These differences in level of significance are 
probably due to model-dependent differences in the 
determination of the AUC. In the compartmental analysis the 
AUC is determined from the regression parameters (AUC = A/a 
+ B/ ) whereas the AUC in the non-compartmental analysis 
was calculated by the trapezoidal rule. For the tralpezoidal 
rule, the area from the time of the last data point to 
infinite time was calculated using the 12. determined from the 
slope of the terminal linear portion of the semilogarithmic 
plot of concentration-time data. With the longer 
distribution half-life (tic)  during ambulation (Table 3.6), l 
it is possible that the P. calculation for that phase 
includes a greater distribution factor than during either 
sleep or bedrest in spite of only data beyond 180 minutes 
post-dose being used in the calculations. Substitution of 
the 	from the two-compartment analysis in the calculation 
of AUC by the trapezoidal rule suggests that this may be the 
case. In that substitution the AUC for sleep was 802.7 ± 
184.9 (compared to 800.1 ± 177.0) and for bedrest was 802.0 
± 166.8 (compared to 800.6 ± 154.2) whereas for ambulation 
the difference was greater, 694.1 ± 232.2 (compared to 617.4 
± 155.1), (Table 3.6). 
The clearance of gentamicin during ambulation tended to be 
53 
greater than during either bedrest or sleep (Tables 3.6 and 
3.7). Factors that could account for changes in gentamicin 
clearance with changes in posture or sleep are alterations 
in glomerular filtration rate, urinary pH, urine flow or 
changes in the distribution rate giving an apparent change 
in clearance. As glomerular filtration rate appears to be 
independent of posture or exercise (Radigan & Robinson, 
1949; Swartz & Sidell, 1973) and gentamicin clearance is not 
affected by urinary pH (Mariel et al, 1972) and in the 
present study there was no correlation between urine flow 
rate and clearance (r = 0.25, p = 0.15), the changes in 
clearance may be reflecting altered distribution. 
Gentamicin is a complex consisting of three major 
components, gentamicins C l , C ia and C 2 and several minor 
components (Wilson et al, 1973a; Anhalt et al, 1978) and 
most official monographs do not set any limits on the 
relative proportions of the components allowed in the 
complex. The United States Pharmacopeia (1984) allows the 
proportion of each component within a commercial batch of 
the drug to vary within quite wide limits (C 1 , 25-50%; C la , 
15-40%; C 2' 20-50%). Variations between commercial batches 
have been confirmed by several workers (Anhalt et al, 1978; 
Kantor & Selzer, 1968; Wilson et al, 1973a). Thus, each 
time gentamicin is administered, the disposition of the 
total complex depends on the individual pfiarmacokinetic 
properties of three chemical entities and their relative 
proportion in the complex. Michelson et al (1976) suggested 
that these variations in percentage of the major components 
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between commercial batches of gentamicin and possible 
differences in the pharmacokinetic properties may account 
for the wide variability of serum gentamicin levels reported 
in the literature. If the antibacterial potency of the 
components also varied, then this could have important 
clinical consequences. In fact, in vitro studies of the 
susceptibilities of various microorganisms to the individual 
components C l , C la , C 2 have indiciated a range of minimum 
inhibitory concentration ratios (Waitz & Weinstein, 1969). 
Very few studies have examined the pharmacokinetics of the 
gentamicin components and none have studied the effect of 
posture or sleep on their disposition. Mosegaard et al 
(1975) compared the efficacy and pharmacokinetics of 
gentamicin complex and gentamicin C l . In that study the 
efficacy of gentamicin complex and gentamicin C 1 appeared to 
be similar, however, there appeared to be some differences 
in the disposition of the two gentamicin dosage forms. 
Serum concentrations of gentamicin complex were generally 
higher than those for gentamicin C l . The volume of 
distribution of gentamicin C 1 (25 ± 1.5% of body weight) was 
47% greater than that of gentamicin complex (17 ± 1% of body 
weight) and the total body clearance of gentamicin C 1 (57 ± 
8 ml/min) was also considerably greater than that of 
gentamicin complex (35 ± 4 ml/min). However, the half-lives 
of the two agents were comparable. 
Nation et al (1978) compared the disposition of gentamicin 
55 
C 1  and the other two components (C ia , C 2 ) combined. The 
components C la and C 2 could not be resolved in that study 
with the evaluation being restricted to reporting the ratios 
of the peak height for C 1 to the peak height for C la C 2 for 
a limited number of blood samples from patients. Based on 
these results and a study in a single rabbit, Nation et al 
(1978) concluded that as there was little difference in the 
ratios in the patient samples and little change over 5 hours 
in the rabbit samples that the disposition of gentamicin C 1 
was similar to gentamicins C ia and C 2 . 
Examination of the results for the components in this study 
(Table 3.7) showed that, for each component, the volume at 
steady state (V ss ) and total body clearance (CL B ) were 
significantly greater during ambulation than during either 
supine state. Although there was a trend towards gentamicin 
C2 to have a greater V and smaller CL thantha  the other ss 
components, this trend did not reach statistical 
significance in any of the states examined. These trends 
were, however, reflected in the mean residence time (MRT) 
where the MRT for gentamicin C 2 was significantly longer 
than for gentamicin C 1 in all states and than gentamicin C ia 
during ambulation and bedrest. There may be some 
correlation between gentamicin C 2 having the longest mean 
residence time and the toxicity of this component observed 
by Kohlhepp et al.(1984). Preferential binding to the 
kidney or greater accumulation of this component in the body 
on multiple dosing may result in its greater toxicity. 
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Very few systematic human studies on the influence of sex 
and the effect of menstrual cycle on drug kinetics have been 
reported (Giudicelli & Tillement, 1977). Giudicelli & 
Tillement (1977) suggested that the half-life of gentamicin 
was shorter in females than in males. In a study of 1,640 
patients, Zaske et al (1982) found that females eliminated 
gentamicin more rapidly than males and that there were sex-
related differences in half-life, clearance and volume of 
distribution. The half-life of another aminoglycoside, 
kanamycin, was also reported to be shorter in females than 
in males (Nielson et al, 1973). In the present study, 
although the mean half-life of total gentamicin in females 
is shorter than the mean half-life in males (Table 3.8), 
there was no significant difference in half-life or any 
other pharmacokinetic parameter determined for total 
gentamicin between males and females. Figure 3.7 shows that 
the mean serum gentamicin levels for females investigated in 
this study were lower than those for males at all times. 
However, more detailed examination of the data reveals that 
only the AUC for gentamicin C 1 for females differed 
significantly from that for males (Table 3.8). In this 
study a dose was used in accordance with the reported better 
correlation between the volume of distribution and subjects' 
lean body mass than with total body weight (Hull & Sarubbi, 
1976). Other workers have suggested that a hybrid of lean 
body mass and total body weight should be used to calculate 
aminoglycoside doses to account for the extracellular fluid 
contained in adipose tissue (Bauer et al, 1980; Blouin et 
al, 1979; Korsager, 1980; Schwartz et al, 1978). The males 
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in the present study had little adipose tissue (TBW:LBM, 
range 1.10 - 1.17) whereas the females had a considerably 
higher fraction of adipose tissue (TBW:LBM, range 1.38 - 
1.54). The females had a slightly higher volume of 
distribution (0.28 ± 0.07 1/kg LBM) than males (0.27 ± 0.11 
1/kg LBM) based on ideal body weight suggesting some 
distribution into adipose tissue, although this difference 
did not reach significance. In the work of Zaske et al 
(1982), the dose was administered on a basis of total body 
weight and pharmacokinetic analysis used a one-compartment 
model. If the females in that study had a higher proportion 
of their body weight as adipose tissue than the males, a 
smaller volume of distribution per kilogram of total body 
weight in females might be expected (Schwartz et al, 1978). 
Recently, Bauer et al (1978) studied aminoglycoside kinetics 
in morbidly obese subjects and observed that obese patients 
had considerably higher volumes of distribution than normal 
weight subjects but that it was difficult to apply a fixed 
correction factor and some subjects were best dosed using 
ideal body weight while others should be dosed using total 
body weight. 
There have been very few studies into the influence of 
menstrual cycle on the disposition of drugs. Most of the 
studies have investigated drugs eliminated by metabolism 
such as paracetamol (Wojcicki et al, 1979), antipyrine 
(Riester et al, 1980) and nitrazepam (Jochemsen et al, 
1982). Although for nitrazepam and paracetamol there were 
minor changes in some of the pharmacokinetics of the drugs 
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associated with different phases of the menstrual cycle, 
these changes were not statistically significant (Jochemsen 
et al, 1982; Wojcicki et al, 1979). Tegeris & Panteleakis 
(1973) reported that, following oral administration of the 
drug, menstruating women had lower plasma levels of 
ampicillin (a drug eliminated predominantly by the kidney) 
at certain times after dosing than when non-menstruating. 
Complete details of the study were not given. Towards the 
end of a menstrual cycle, there appears to be localised 
oedema and changes in fluid distribution rather than changes 
in total body water, although many women report weight gain 
and generalised oedema in the pre-menstruum (Reid & Yen, 
1981; Friedman, 1984). These changes in fluid distribution 
throughout the menstrual cycle may lead to alterations in 
the apparent volume of distribution of polar, water-soluble 
drugs such as gentamicin. Although the number of subjects 
in the present study was small, this was the trend observed. 
However this change was only significant for gentamicin 
component C la• The clearance of the drug also tended to be 
higher during the luteal phase thus causing no apparent 
change in the elimination half-life (Table 3.8). 
The only component for which the clearance during the second 
half of the menstrual cycle was significantly higher than 
during the first half of the cycle, was gentamicin C l . The 
mean clearance of this component during the luteal phase was 
nearly double the mean clearance during the follicular 
phase. The mean clearances of the other components altered 
by 30 to 50%. A doubling of the clearance would result in a 
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halving of the steady state concentration of that component 
on chronic dosing. Such an effect could have clinical 
consequences especially in batches of gentamicin containing 
50% gentamicin C l . 
Although the differences in disposition between the major 
gentamicin components appear to be minor, the finding of 
gentamicin C 2 having a longer mean residence time than the 
other components may be clinically important in the light of 
the findings of Kohlhepp et al (1984) which showed that 
gentamicin C 2 is the most nephrotoxic of the components. 
The effects of posture could result in ambulant subjects 
requiring a larger loading dose (50 - 100% greater) than 
supine subjects and possibly higher maintenance doses to 
offset the higher clearance during ambulation. These 
results highlight the need to routinely monitor gentamicin 
levels rather than rely on nomograms or fixed dosage 
schedules. 
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CHAPTER 4 
BENZYLPENICILLIN 
4.1: INTRODUCTION 
4.1.1: DRUG PROFILE 
Benzylpenicillin (Penicillin G) is the only natural 
penicillin in clinical use. In spite of the introduction of 
newer f3-lactam penicillins with either a wider spectrum of 
activity or increased activity against penicillinase-
producing bacteria, benzylpenicillin is still frequently 
considered to be the drug of choice for the treatment of 
infections due to susceptible organisms (Wise, 1982; Ball, 
1982). The penicillins bind to target sites on the 
cytoplasmic membranes of susceptible bacteria and interfere 
with peptidoglycan synthesis. This action results in a 
weakened cell wall which bursts from internal pressure. 
Thus, the penicillins have a bactericidal action 
(McAllister, 1982). 
Benzylpenicillin is virtually free of toxicity at all usual 
doses. At very high doses (greater than 20-million units 
per day) some central nervous system side effects have been 
noted but these are more likely to occur in the presence of 
renal insufficiency or pre-existing central nervous system 
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lesions (Mandell 	Sande, 1980). The most common adverse 
reactions to benzylpenicillin are those involving 
hypersensitivity. Although severe hypersensitivity 
reactions such as anaphylaxis may occur, the usual reactions 
are mild to moderate skin manifestations (Ibister, 1971). 
4.1.2: ASSAYS 
Several high-performance liquid chromatographic (HPLC) 
methods for the determination of benzylpenicillin in dosage 
forms or as pure drug have been reported (White, Carroll & 
Zarembo, 1977; Nachtmann & Gstrein, 1980; Ghebre-Sellassie, 
Hem & Knevel, 1982). In studies examining various aspects 
of the pharmacokinetics of benzylpenicillin, the usual 
method for assay of the drug has been microbiological 
(Schmidt & Roholt, 1966; McCarthy & Finland, 1960; Cole, 
Kenig & Hewitt, 1973; Kates et al, 1980). Microbiological 
assays are slow and also suffer from a lack of selectivity 
and low precision (Westerlund, Carlqvist & Theodorsen, 
1979). HPLC has the advantage of being rapid, highly 
selective and usually more precise than microbiological 
assays. HPLC assays have been developed for a number of 
penicillins in biological fluids (Westerlund et al, 1979; 
Vree et al, 1978c; Thijssen, 1980; Uno et al, 1981; Teare et 
al, 1982) but only that of Westerlund et al (1979) assays 
benzylpenicillin: The method of Westerlund et al (1979) 
involves post-column derivatisation, a process which 
requires special equipment and techniques which are often 
not available. The method described below (section 4.2) 
describes a simple, rapid and selective HPLC assay for the 
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determination of benzylpenicillin in plasma and urine. 
4.1.3: PHARMACOKINETICS 
Benzylpenicillin is acid-labile and, thus, much of an orally 
administered dose is destroyed by the gastric secretions. 
Absorption following an oral dose is variable and 
unpredictable (Barza & Weinstein, 1976). Consequently, 
benzylpenicillin is now administered predominantly by 
parenteral means. 
Once in the sytemic circulation, benzylpenicillin is widely 
distributed throughout the body with an apparent volume of 
distribution equivalent to about 50% of body water (Mandell 
& Sande, 1980). It is about 60% bound to plasma proteins 
(Barza & Weinstein, 1976). 
Benzylpenicillin is rapidly eliminated from the body, mainly 
by the kidney where it is actively secreted into the renal 
tubule as well as filtered at the glomerulus. The active 
secretion can be blocked by administration of probenecid. 
Some metabolism occurs and Cole et al (1973) found 
approximately 19% of an intramuscularly administered dose 
was converted to penicilloic acid. 
The disposition of benzylpenicillin apppears to be affected 
by posture or exercise. Schmidt & Roholt (1966) observed 
that the serum levels of benzylpenicillin, following 
intramuscular administration, were higher during ambulation 
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than during bedrest. Levy (1967) suggested that these 
differences could be due to posture-dependent alterations in 
certain physiological parameters such as renal blood flow. 
Kates et al (1980) studied the effects of prolonged 
recumbency on benzylpenicillin pharmacokinetics and found 
that seven days recumbency had no effect on the disposition 
of the drug. The effects of posture on the disposition of 
other penicillin have been studied. Roberts & Denton (1980) 
found that following an oral dose, serum amoxycillin levels 
were significantly higher during ambulation than during 
either bedrest or sleep. Pharmacokinetic analysis showed 
increased total serum clearance and renal clearance in 
supine subjects. Those results were attributed to a 
diminished renal blood flow when subjects are ambulant. 
Breiby et al (1983) administered ampicillin intravenously to 
subjects while sitting and while supine and found no changes 
in clearance but some differences in distribution with 
change in posture. It is of interest that the two studies 
in which the greatest changes in drug disposition were 
observed, were those in which the penicillins were 
administered extravascularly (Schmidt & Roholt, 1966; 
Roberts & Denton, 1980). 
This study was undertaken to examine the effects of posture 
(bedrest and ambulation) on the pharmacokinetics of 
benzylpenicillin following both intravenous and 
intramuscular administration. Comparison of the resultant 
pharmacokinetics allows the effects of posture on absorption 
to be separated from the effects of posture on disposition. 
As Roberts & Denton ( 1980) reported no significant 
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differences between the pharmacokinetics of amoxycillin 
during bedrest and those during sleep, the disposition of 
benzylpenicillin during sleep was not evaluated in the 
study. 
4.2: ANALYSIS 
4.2.1: MATERIALS & METHODS 
4.2.1.1: Chemicals 
Benzylpenicillin was supplied by Commonwealth Serum 
Laboratories (Australia). Methanol and acetonitrile were 
specially purified for HPLC and supplied by Waters 
Associates (Milford, MA, USA). All other chemicals were 
analytical grade. The water used was de-ionized then glass 
distilled. Benzylpenicilloic acid, the major metabolite of 
benzylpenicillin, was prepared according to the method of 
Cole et al (1973). 
4.2.1.2: HPLC instrumentation and conditions 
Reversed-phase HPLC was performed using a Waters M-6000A 
solvent delivery system fitted with a U6K injector. A C 18 
pBondapak column (particle size 10 pm; 300 mm x 3.9 mm I.D; 
Waters Associates, Milford, MA, USA) was used in combination 
with a guard column (pBondapak C 18 /Porasil B; Waters 
Associates, 23 mm x 3.9 mm I.D.) in all studies. UV 
absorbance at 214 nm was monitored with a Waters Model 441 
UV absorption detector fitted with a Zinc lamp. The 
absorbance was recorded on a dual-channel Omniscribe 
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recorder (Houston Instruments, Austin, TX, USA). Injections 
were made with a 25 pl Hamilton syringe. The mobile phase 
was 0.015M phosphate buffer (pH 7.0 ± 0.1)-methanol (72:30) 
mixture. The flow rate was 1 ml/min. 
4.2.1.3: Sample Preparation 
Plasma and urine samples were processed by transferring a 
200p aliquot of the sample into a glass tube (disposable 
borosilicate glass culture tubes; 6 x 50 mm; Kimble, IL, 
USA) and adding an equal volume of acetonitrile. The sample 
was vortexed for 1 minute then centrifuged at 1500g for 5 
min. An aliquot (20p1 for plasma, 10p1 for urine) of clear 
supernatant was injected onto the column. 
4.2.1.4: Preparation of Standard Curve's 
Plasma standards were prepared at the start of each day by 
spiking drug-free plasma with known amounts of freshly 
prepared aqueous solution of benzylpenicillin to produce 
concentrations of 0.5-50 mg/l. The standards were then 
assayed in the described manner. Urine standards were 
prepared in a similar manner in drug-free urine to produce 
concentrations of 20-4000 mg/l. Standard curves were 
prepared by plotting the peak height of benzylpenicillin 
versus concentration. 
4.2.2: RESULTS 
Typical chromatograms of blank plasma and plasma from a 
subject following intravenous administration of 
benzylpenicillin are shown in Figure 4.1. 
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Figure 4.1 Chromatograms of (a) blank plasma and (b) plasma 
from the same subject 30 minutes after intravenous 
administration of 600 mg benzylpenicillin. The plasma 
concentration of benzylpenicillin is estimated to be 7.3 mg/1 
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Figure 4.2 Chromatograms of (a) blank urine and (b) urine 
from the same subject collected from 0 - 8 hours after 
intravenous administration of 600 mg benzylpenicillin. The 
urine concentration of benzylpenicillin is estimated to be 
1310 mg/l. The arrow indicates change in absorbance scale. 
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The retention time for benzylpenicillin is 12.4 minutes. 
Figure 4.2 shows chromatograms of blank urine and urine 
following administration of benzylpenicillin, from the same 
subject. 
Over the concentration ranges studied (0-50 mg/1 for plasma 
and 0-4000 mg/1 for urine), linearity of response was found 
to be good (r>0.99) and consistently reproducible for 
standard curves based on peak height following injection of 
a known volume of supernatant (Figures 4.3 & 4.4). 
Under the conditions of this assay, the detection limit for 
benzylpenicillin in plasma was 0.2 mg/l. 0.5 mg/1 could be 
determined quite readily and reproducibly. In urine the 
detection limit was about 10 mg/l. 
The intra- and inter-day reproducibility of the assay for 
plasma are shown in Table 4.1. The intra-day coefficients 
of variation for benzylpenicillin in urine at concentrations 
of 2000 mg/1, 200 mg/1 and 20 mg/1 were 2.74%, 1.69% and 
8.5%, respectively (n = 6). 
4.2.3: DISCUSSION 
Several HPLC assays for benzylpenicillin in non-biological 
fluids have used UV detection at 254 nm (Ghebre-Sellassie et 
al, 1982; White et al, 1977; Blaha et al, 1976). It was 
found using the present system that a greater than twenty-
fold increase in sensitivity could be achieved by monitoring 
the effluent at 214 nm rather than at 254 nm without 
increased interference or baseline noise. UV detection in 
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Figure 4.3 Standard curve for benzylpenicillin in plasma 
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Figure 4.4 Standard curve for benzylpenicillin in urine 
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Table 4.1 Intra- and inter-day variation of 
benzylpenicillin in plasma. 
Concentration 
mg/1 
Intra-day CV(%) 
(n=6) 
Inter-day CV(%) 
(n=5, 	over 2 weeks) 
20 2.53 3.59 
10 2.26 4.89 
4 1.69 5.81 
1 7.30 9.16 
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the range of 210-230 nm has been used by other workers (Vree 
et al, 1978c; Thijssen, 1980; Teare et al, 1982; Uno et al, 
1981) to quantitate various other penicillins in biological 
fluids. 
A number of agents may be used to precipitate plasma 
protein. In HPLC assays for other penicillins, perchloric 
acid (Vree et al, 1978c), trichloroacetic acid (Westerlund et 
al, 1979) and acetonitrile (Teare et al, 1982) have been 
used. In the present study, acetonitrile was found to 
completely precipitate plasma protein and provided the 
cleanest chromatogram. Acetonitrile was also added to urine 
samples to reduce the number of endogenous peaks. The usual 
method for the determination of benzylpenicillin in 
biological fluids is by microbiological means. Such assays 
have a low precision with an experimental error of ± 15% and 
their selectivity is reduced if active metabolites or other 
compounds with antibacterial activity are present 
(Westerlund et al, 1979). Except at plasma benzylpenicillin 
concentrations of 1 mg/1 or less, the present assay had an 
intra-day coefficient of variation of less than 5% and the 
inter-day coefficient of variation was less than 10% for all 
concentrations (Table 4.1). The inter-day coefficient of 
variation could be reduced to that of the intra-day by 
preparing standard curves on each day of assay. The 
selectivity of this method was studied by measuring the 
retention times of other common penicillins. Those times 
are shown in Table 4.2. Modification of the polarity of the 
mobile phase could make this system suitable for the assay 
of these compounds. 
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Table 4.2 Retention times of various penicillins 
Penicillin Retention time 
(minutes) 
Ampicillin 6.0 
Methicillin 9.2 
Benzylpenicillin 12.4 
Amoxycillin 14.4 
Oxacillin 26.0 
Cloxacillin 37.2 
Flucloxacillin 40.0 
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This method was used in the following study to follow the 
disposition of benzylpenicillin administered intravenously 
and intramuscularly. The plasma benzylpenicillin-time 
profiles for volunteers following intravenous administration 
showed levels similar to those obtained by Kates et al 
(1980) following intravenous administration of the same dose 
but using a microbiological assay. 
In summary, this HPLC assay provides a selective, reliable 
and reproducible method for the rapid determination of 
benzylpenicillin in plasma and urine. The method does not 
require time-consuming or complex extraction or 
derivatisat ion techniques. 
4.3: PHARMACOKINETIC STUDY 
4.3.1: CLINICAL PROTOCOL 
4.3.1.1: Subjects 
Eight healthy, young adult volunteers (four male, four 
female) aged 21-23 years, participated in the study. Prior 
to the investigation, a detailed medical history was taken 
with particular attention to possible penicillin allergy. 
Subjects with a history of drug allergy, eczema and hayfever 
were excluded from the study. No subjects gave a history of 
liver or renal disease. Physical examination, 
haematological tests and tests for liver and renal function 
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showed no abnormality. No other drugs were taken during the 
two weeks preceding the study or during the study. Informed 
consent was obtained from each subject and approval from the 
Human Ethics Committee of the University of Tasmania was 
obtained before commencing the study. 
4.3.1.2: Procedure 
Each subject was given 600mg benzylpenicillin on four 
separate occasions - by intravenous administration during 
bedrest and during ambulation and by intramuscular 
administration during bedrest and during ambulation. To 
avoid any possible variations in physiological parameters 
due to food intake the studies were commenced after an 
overnight fast and no food was permitted for two hours after 
dosing. At least one week elapsed between each study. The 
investigation was conducted in a cross-over design and each 
subject served as its own control. The dose was 
administered after the subjects had been either lying or 
standing for one hour. Changes in posture were not allowed 
throughout each phase of the study, with ambulant subjects 
being allowed to sit only for short periods. As caffeine 
appeared to interfere with the assay for benzylpenicillin, 
subjects refrained from caffeine-containing beverages 
overnight before each study and during each study. 
4.3.1.3: Sample collection 
An indwelling catheter was inserted into an antecubetal 
vein, approximately one hour before dosing. During the 
intravenous phases of the study the cannulae were inserted 
into the opposite arm to that used for dosing. Patency of 
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the cather was maintained by flushing with a small volume of 
heparinised saline (10 IU/ml) after each blood sample was 
collected. 5m1 blood samples were drawn at 0, 10, 20, 30, 
45, 60, 90, 120, 150, 180, 240 minutes after dosing. To 
avoid contamination of the blood sample with heparinised 
saline, the first 1.0m1 of blood was drawn separately and 
discarded. All samples were placed into heparinised tubes 
and immediately centrifuged. The plasma was stored at -20 °C 
until assayed. 
All urine excreted by the subjects 0-8 hours and 8-24 hours 
was collected, measured and an aliquot stored at -20 °C until 
assayed. Samples of serum and urine were assayed for 
benzylpenicillin as soon as possible after collection. 
4.3.1.4: Pharmacokinetic and statistical analysis 
Intravenous data 
The plasma benzylpenicillin concentration (C) versus time 
(t) data, obtained following intravenous administration of 
the drug, were fitted to a biexponential equation of the 
following form: 
C = Ae -at  + Be -8t 
	(4.1) 
corresponding to a 2-compartment open model. All data were 
fitted using a non-linear least-squares regression computer 
program (FUNFIT). The calculated values of A, B, a and 8 
were used to estimate the half-life of the 8-phase (t 1/2 ), 
body clearance (CL B ), apparent volume of distribution (V), 
77 
volumes of the central compartment (V c ) and tissue 
compartment (V t ), distribution rate constants (k 12 and k21 ) 
and the elimination rate constant (K 10 ). 
The area under the concentration-time curve (AUC) used in 
the compartmental analysis was calculated using the 
regression parameters from Equation 4.1. 
AUC = A/a + B/8 	 (4.2) 
whereas the AUC and AUMC used in statistical moment 
analysis were calculated by the trapezoidal rule with 
appropriate correction for the partial area from the final 
data point to infinity based on the slope of the terminal 
exponential phase (Gibaldi & Perrier, 1982b). The mean 
residence time (MRT) is given by (Gibaldi & Perrier, 1982b) 
MRT = 
AUMC ortCdt (4.3) 
AUC ofmCdt 
The renal clearance of benzylpenicillin (CL R ) was estimated 
from the ratio of amount of unchanged drug excreted in the 
urine to infinite time (Xu ) to the area under the plasma 
benzylpenicillin concentration versus time curve (AUC) 
(Equation 4.4). For this calculation it was assumed that 
urine collected over 24 hours was equivalent to infinite 
time. 
Xu  CL R = AUC 
(4.4) 
78 
f .CL. 	+ Q s 	int 	R 
f .CL. 	.Q s 	int R CL R - (4.5) 
The dependence of renal clearance on flow was examined using 
the "well-stirred" model for clearance (Gibaldi & Perrier 
1982a) and the corresponding equation given by Roberts & 
Denton (1980). 
where f s is the fraction of unbound drug, CL int is the renal 
intrinsic clearance and Q R is the effective renal blood 
flow. As benzylpenicillin excretion is primarily by tubular 
secretion and is largely independent of protein binding 
(Craig and Welling, 1977) the term f s is approximated to 
unity. Equation 4.5 was used to examine the dependence of 
renal benzylpenicillin clearance on renal blood flow changes 
induced by posture. 
Intramuscular data 
The overall elimination rate constant (8) was determined 
from the slope of the terminal linear segment of a semi-
logarithmic plot of plasma concentration versus time. The 
elimination half-life (t,) was then calculated in the usual 
manner (t, = 0.693/8). 
The area under the plasma benzylpenicillin concentration 
versus time curve (AUC) was determined using the trapezoidal 
rule with appropriate correction for the partial area from 
the final data point to infinity based on the slope of the 
terminal exponential phase (Gibaldi & Perrier, 1982b). 
Since benzylpenicillin was administered intramuscularly in 
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the present study, its apparent volume of distribution could 
not be estimated directly. The ratio of the apparent volume 
of distribution for benzylpenicillin (V) to its extent of 
absorption into the systemic circulation (F) was calculated 
according to Equation 4.6. 
V/F =  	 (4.6) 
.AUC 
where D is the administered dose and AUC is the area under 
the plasma benzylpenicillin concentration versus time curve. 
For each subject, the area under the plasma benzylpenicillin 
concentration versus time curve following intramuscular 
administration (AUC im ) was compared with the area under the 
plasma benzylpenicillin concentration versus time curve 
following intravenous administration of the same dose 
(AUC. ). From this comparison, the bioavailability of iv 
benzylpenicillin from the intramuscular site could be 
determined. 
AUC. 
F = 	im (4.7) 
AUC. iv 
By substitution of F into Equation 4.6, the apparent volume 
of distribution for each subject was determined. The 
bioavailability of benzylpenicillin was also used to 
calculate the total body clearance (CL B ) of benzylpenitillin 
80 
according to Equation 4.8. 
CLB = 
F.D 
AUC 
(4.8) 
The renal clearance of benzylpenicillin, following 
intramuscular administration, was calculated according to 
Equation 4.4 and the dependence of the renal clearance on 
renal plasma flow was examined using Equation 4.5. 
Using data from the intravenous dosing phases of this study, 
the fraction remaining to be absorbed at various times was 
determined according to the Loo-Riegelman method (Loo & 
Riegelman, 1968). The rate of absorption was calculated 
from linear regression of these data. Extrapolation of the 
linear regression of the data allowed the lag time for 
absorption to be determined. The lag time was taken to be 
the time at which the fraction remaining to be absorbed 
equalled 1.00. The peak time (corrected for lag time) was 
also used to reflect the rate of absorption of 
benzylpenicillin. 
The non-compartmental pharmacokinetic parameter, mean 
residence time (MRT), based on statistical moment theory, 
was calculated'from the AUC and AUMC and is given by 
Equation 4.3. The mean absorption time (MAT) was determined 
from Equation 4.9 (Riegelman & Collier, 1980) for the seven 
subjects using the mean residence times determined from both 
intramuscular and intravenous data. 
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MAT = MRT. 	- MRT. 	 (4.9) im iv 
The mean urinary flow rate for each subject was calculated 
from the urine volume collected during the first eight hours 
after drug administration. 
Statistical comparison of the effect of bedrest and 
ambulation on various pharmacokinetic parameters was made by 
Wilcoxon's test for paired observation. 
4.3.2: RESULTS 
The mean plasma benzylpenicillin levels versus time profiles 
for bedrest and ambulation following intravenous 
administration of benzylpenicillin are shown in Figure 4.5. 
Due to problems with venous spasm preventing blood sample 
collection from one subject, these profiles represent the 
data of only seven subjects. Although at all times the mean 
plasma benzylpenicillin concentrations were lower during 
bedrest than during ambulation, these concentrations were 
not significantly different (p>0.05). 
Following intramuscular administration of the drug, the 
plasma benzylpenicillin concentrations during bedrest were, 
again, lower at all times, except at 10 minutes after 
dosing, than during ambulation (Figure 4.6). The 
concentrations were only significantly different at 45 
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Figure 4.5 Mean (±SD) plasma benzylpenicillin 
concentrations found in seven healthy subjects during 
A ambulation and 0 bedrest following intravenous 
administration of 600 mg benzylpenicillin 
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Figure 4.6 Mean (±SD) plasma benzylpenicillin 
concentrations found in eight healthy volunteers during 
A ambulation and 0 bedrest following intramuscular 
administration of 600 mg benzylpenicillin 
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minutes post-dosing (p<0.05). 
The mean experimental and pharmacokinetic data for each of 
the parameters determined during bedrest and ambulation, 
following both intravenous and intramuscular dosing, are 
shown in Tables 4.3 and 4.4, respectively. Individual 
experimental and pharmacokinetic data are presented in 
Tables 4.5 (i.v., ambulation), 4.6 (i.v., bedrest), 4.7 
(i.m., ambulation) and 4.8 (i.m., bedrest). 
There was no significant difference between the values 
obtained during bedrest and ambulation for any of the 
pharmacokinetic parameters determined when the dose was 
administered intravenously. 
In the pharmacokinetic analysis of the data obtained 
following intramuscular administration of benzylpenicillin, 
several of the pharmacokinetic parameters required the use 
of data from the intravenous-dosing phase of the study. The 
results for those parameters represent only the seven 
subjects for whom complete intravenous data was available. 
Comparison of bedrest and ambulation values of the 
pharmacokinetic parameters determined after intramuscular 
dosing showed that the area under the plasma 
benzylpenicillin concentration versus time curve (AUC im ) for 
ambulation was significantly larger than the AUCim for 
bedrest (p<0.05). Otherwise there were no significant 
differences between any of the pharmacokinetic parameters 
determined from the intramuscular data. 
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Table 4.3 Comparison of mean estimates (±SD) of 
pharmacokinetic data for benzylpenicillin in seven subjects 
following intravenous administration of the dose (from 
Tables 4.5 & 4.6) 
Parametera Ambulation 	Bedrest 
k 12 (10
-2min -1 ) 1.34 ± 	0.73 1.74 ± 	0.89 
k21 (10
-2min -1 ) 2.39 ± 	1.19 2.43 ± 	0.99 
k 10 (10
-2min -1 ) 4.58 ± 	1.23 4.98 ± 	1.03 
AUC (min.mg/1) 1278 ± 	273 1153 ± 	262 
V 	(1/kg) 0.58 ± 	0.41 0.73 ± 	0.76 
Vc 	(1/kg) 0.17 ± 	0.07 0.17 ± 	0.06 
t1/2 i3 (min) 53.6 ± 	32.3 54.2 ± 	36.1 
CLB (ml/min) 487.4 ± 	100.5 543.6 ± 	122.6 
CLR (ml/min) 309.4 ± 	93.4 324.1 ± 	145.3 
CLNR (ml/min) 178.0 ± 	51.3 218.2 ± 	66.5 
0.63 ± 	0.12 0.58 ± 	0.17 
MRT (min) 36.23 ± 	13.45 35.27 ± 	10.21 
a k 12 and k21 - apparent first-order intercompartmental 
distribution rate constants; k lo - apparent first order 
elimination rate constant; t 1/2  - elimination half-life; 13 
AUC - area under the plasma concentration-time curve; 
V - apparent volume of distribution; Vc - volume of the 
central compartment; CL B - total body clearance; 
f - fraction of the dose excreted unchanged in the urine; 
CL R - renal clearance; CL NR - nonrenal clearance; 
MRT - mean residence time 
86 
Table 4.4 comparison of mean estimates (±SD) of 
pharmacokinetic data for benzylpenicillin in eight subjects 
following intramuscular administration of the dose (from 
Tables 4.7 & 4.8) 
Parameter a Ambulation 	Bedrest 
V(1/kg) 0.55 ± 	0.18 
CLB
b 	(ml/min) 487.6 ± 	100.9 
0.46 ± 	0.12 
CL R (ml/min) 264.3 ± 	99.7 
CLNR
b (ml/min) 233.6 ± 	81.3 
MRT (min) 
b 	. MAT 	(min) 
100.9 
65.7 
± 	21.4 
± 	33.3 
50.9 ± 19.3 
1032 ± 204 
0.64 ± 0.19 
0.95 ± 0.10 
0.62 ± 0.25 
544.0 ± 122.7 
0.55 ± 0.09 
314.6 ± 87.4 
236.9 ± 108.4 
96.7 ± 29.8 
63.8 ± 32.3 
t 1 	(min) 
c 	. AUC (min.mg/1) 
V/F (1/kg) 
Fb 
b 
52.5 ± 11.7 
1175 ± 256 
0.63 ± 0.22 
0.93 ± 0.11 
- elimination half-life; AUC - area under the plasma 
concentration-time curve; V/F - apparent volume of 
distribution (V) divided by the fraction of dose absorbed 
(F); F - fraction of the dose absorbed; V - apparent volume 
of distribution; CL B - total body clearance; f - fraction of 
the dose excreted unchanged in the urine; CL R - renal 
clearance; CL NR - nonrenal clearance; MRT - mean residence 
time; MAT - mean absorption time 
n = 7 
p<0.05 
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Table 4.5 Experimental and pharmacokinetic data describing the disposition of 
benzylpenicillin in ambulant subjects following intravenous administration of the dose. 
Parametera 	 Subject 
AU NW AC BM CJ SB CL 
Sex F F F M M M M 
Age 21 23 21 21 22 21 22 
Weight 	(kg) 54 60 67 70 72 68 75 
-2 k 12 	(10 	min
-1  ) 0.70 2.37 1.18 1.35 0.54 2.28 0.94 
-2 	-1 k21 	(10 	min 	) 1.27 3.92 2.73 3.72 0.71 1.97 2.43 
-2 	-1 k 10 	(10 	min 	) 3.78 5.62 5.02 4.38 2.76 6.47 4.05 
AUC 	(min.mg/1) 1721 986 1190 1333 974 1520 1224 
V 	(1/kg) 0.64 0.44 0.38 0.28 1.48 0.43 0.38 
Vc 	(1/kg) 0.17 0.18 0.15 0.15 0.31 0.09 0.16 
t, 	(min) 68.4 30.2 35.1 30.5 120.2 50.8 40.0 18 
CL B 	(ml/min) 348.7 608.5 504.0 450.3 615.9 394.8 490.0 
CL R (ml/min) 157.2 423.0 373.2 313.0 386.3 275.7 237.7 
CL NR 	(ml/min) 191.5 185.5 130.8 137.3 229.6 119.1 252.3 
f 0.45 0.70 0.74 0.70 0.63 0.70 0.48 
MRT 	(min) 39.77 27.20 26.73 29.80 65.03 31.32 33.78 
a Parameters as defined in Table 4.3 
Table 4.6 Experimental and pharmacdkinetic data describing the disposition of 
benzylpenicillin in bedrested subjects following intravenous administration of the dose. 
Parametera 
AU NW AC 
Subject 
BM CJ SB CL 
Sex F F F M m m m 
Age 21 23 21 21 22 21 22 
Weight 	(kg) 54 60 67 70 72 68 75 
-2 	-1 k 12 	(10 	min 	) 0.88 0.94 2.12 2.10 3.15 2.17 0.80 
k 21 	(10
-2  min -1  ) 2.32 0.64 3.56 2.87 2.79 3.14 1.69 
k10 	(10 	min 	) - 4.04 4.53 6.20 5.50 5.36 5.85 3.37 
AUC 	(min.mg/1) 1573 796 1414 1139 1001 1127 1021 
V 	(1/kg) 0.42 2.43 0.27 0.41 0.54 0.39 0.64 
Vc 	(1/kg) 0.17 0.28 0.10 0.14 0.16 0.13 0.23 
t 	(min) 1113 41.1 133.8 - 30.0 38.0 45.4 34.5 56.3 
CL B 	(ml/min) 381.4 753.7 424.2 526.5 599.4 532.3 587.6 
-CL R 	(ml/min) 229.7 527.5 129.5 285.4 427.2 220.3 449.3 
CL NR 	(ml/min) 151.7 226.2 294.7 241.1 172.2 303.0 138.3 
f 0.60 0.70 0.31 0.54 0.71 0.41 0.76 
MRT (min) 	33.29 	52.84 	24.10 	29.22 	38.41 	27.16 	42.90 
a Parameters as defined in Table 4.3 
Table 4.7 Experimental and pharmacokinetic data describing the disposition of benzylpenicillin 
in ambulant subjects following intramuscular administration of the dose. 
Paramet er a 
AU HW AC 
Subject 
EM BM CJ SB CL 
Sex F F F F M M M M 
Age 21 23 21 21 21 22 21 22 
Weight 	(kg) 54 60 67 73 70 72 68 75 
t 1/26 	(min) 49.2 65.4 43.2 54.0 52.8 31.8 68.4 55.2 
AUC 	(min.mg/1) 1600 920 1325 970 1434 921 1175 1053 
.c, 
0 V/F 	(1/kg) 0.49 1.02 0.44 0.83 0.46 0.43 0.75 0.61 
F 0.93 0.93 1.06 - 1.06 0.93 0.77 0.85 
V 	(1/kg) 0.46 0.95 0.47 - 0.49 0.40 0.58 0.52 
CL B (ml/min) 347.5 606.9 504.8 - 450.5 619.2 396.9 487.6 
f 0.28 0.63 0.38 0.43 0.44 0.47 0.62 0.46 
CL R 	(ml/min) 106.2 409.0 178.7 336.8 188.7 314.3 317.6 263.5 
CLNR (ml/min) 241.3 197.9 326.1 - 261.8 304.9 79.3 224.1 
mRT (min) 101.3 ' 	114.3 88.2 94.01 97.3 64.9 139.0 108.1 
MAT (min) 61.5 87.1 61.5 - 67.5 0.08 107.7 74.3 
a Parameters as defined in Table 4.4 
Table 4.8 Experimental and pharmacokinetic data describing the disposition of benzylpenicillin 
in bedrested subjects following intramuscular administration of the dose. 
Parameter a 	 Subject 
AU HW AC EM BM CJ SB CL 
Sex F F F F M M M M 
Age 21 23 21 21 21 22 21 22 
Weight 	(kg) 54 60 67 73 70 72 68 75 
t
158 
(min) 33.6 46.8 51.6 36.6 42.6 35.4 76.2 84.6 
AUC 	(min.mg/1) 1299 838 1254 720 1060 877 1097 1110 
vz) 1-, V/F 	(1/kg) 0.41 0.80 0.53 0.61 0.50 0.49 0.88 0.88 
F 0.83 1.06 0.89 - 0.93 0.87 0.97 1.09 
V 	(1/kg) 0.34 0.85 0.47 - 0.47 0.43 0.85 0.96 
CL
B 
(ml/min) 380.7 755.0 425.6 - 529.4 596.8 531.4 588.8 
f 0.51 0.49 0.58 0.44 0.63 0.72 0.46 0.53 
CL R (ml/min) 235.6 350.9 275.9 367.3 252.7 496.6 254.0 283.6 
CL
NR
.(ml/min) 145.1 404.1 149.7 - 276.7 100.2 277.4 305.2 
MRT (min) 68.3 93.7 100.9 78.8 73.9 74.8 135.8 147.0 
MAT (min) 35.0 40.9 76.8 - 44.7 36.4 108.6 104.1 
a Parameters as defined in Table 4.4 
Examination of the absorption profile for benzylpenicillin 
following intramuscular administration, using the Loo-
Riegelman method, failed to show any differences between the 
rate of absorption during bedrest and during ambulation 
(Figure 4.7). Table 4.9 gives the mean for peak 
concentration (C ), the time to peak concentration (t ),the 
lag time for absorption (t L ), the time to reach peak plasma 
benzylpenicillin concentration corrected for lag time 
(t 	) and the rate constant for absorption (k a ). In the corr 
determination of several of these parameters, data from the 
intravenous dosing phases of the study were utilized, so, 
for those parameters the values in Table 4.9 are the means 
for only seven subjects. There were no significant 
differences between ambulation and bedrest for any of these 
parameters. 
It was found that the urinary flow rate during bedrest (mean 
± SD: . 1.56 ± 0.32 ml/min) was significantly greater than 
during ambulation (mean ± SD: 0.98 ± 0.40 ml/min) (p<0.05) 
in the intravenous phases of the study. However, the renal 
clearance of benzylpenicillin was not related to urine flow 
rate (r = 0.172, p>0.5 ) (Figure 4.8). 	In the intramuscular 
dosing phases of this study, there was no significant 
difference between the urinary flow rate during ambulation 
(mean ± SD: 0.84 + 0.11 ml/min) and the urinary flow rate 
during bedrest (mean± SD: 0.88 ± 0.37 ml/min). Again, the 
renal clearance of benzylpenicillin was not related to urine 
flow rate (r = 0.004, p>0.5). 
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Figure 4.7 Fraction of the dose remaining to be absorbed 
versus time following intramuscular administration of 600 mg 
benzylpenicillin into the buttock during Li ambulation 
and 0 bedrest 
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Table 4.9 Mean (±SD) pharmacokinetic data describing the 
absorption of benzylpenicillin following intramuscular 
administration of the drug 
Parametera Ambulation 	Bedrest 
Cp 	(mg/1) 
tp 	(min) b 
. 	b t 	(mm) 
	
. 	b (mm) corr 
. 	-1 	b ka (mIn 	) 
9.59 
42.9 
6.40 
36.5 
0.021 
± 	2.55 
± 	9.6 
± 	4.51 
± 	7.7 
± 	0.010 
8.76 
35.7 
7.70 
28.0 
0.0228 
± 	2.92 
± 	15.1 
± 	3.6 
± 	13.4 
± 	0.009 
a Cp - peak plasma concentration of benzylpenicillin; 
tp - time to Cp following intramuscular administration of 
benzylpenicillin; tL - lag time; tcorr  - time to reach peak 
plasma benzylpenicillin concentration corrected for lag 
time; ka - rate constant for absorption 
n = 7 
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Figure 4.8 Renal clearance of benzylpenicillin (CL R ) versus 
urine flow rate during Li ambulation and 0 bedrest 
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In the present study there was no apparent difference in any 
of the pharmacokinetic parameters between male and female 
subjects. 
4.3.3: DISCUSSION 
Limited information is available on the disposition of 
benzylpenicillin following parenteral administration. In 
this work, a specific HPLC analytical procedure to quantify 
the parent drug only was used. The metabolites, penicilloic 
acid and 6-aminopenicillanic acid, are found in the urine 
after oral administration of pencillin G (Cole et al, 1973). 
The pharmacokinetic parameters obtained from this study are 
comparable with those determined in other studies. The mean 
residence time and mean absorption time data presented here 
have not been reported previously. The mean values for the 
terminal half-life found in the present study following 
intravenous administration of the drug (53.6 min during 
ambulation and 54.2 min during bedrest) and following 
intramuscular administration of the drug (52.5min and 50.9 
min during ambulation and bedrest,respectively) are similar 
to those found by Kates et al , (1980) (49.2 min and 51.2 min) 
and also those determined by Levy (1967) in ambulant and 
supine subjects following intramuscular administration of 
benzylpenicillin (50.4 min and 55.8 min respectively). 
The mean values for the volume of distribution during 
bedrest [47.0 1 (i.v.) and 42.0 1 (i.m.)] and during 
ambulation [38.6 1 (i.v.) and 36.4 1 (i.m.)] were very 
similar to those determined by Levy (1967) (47 1 during 
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bedrest and 37 1 during ambulation). Levy, also, was unable 
to show a statistically significant difference between the 
volume of distribution during bedrest and ambulation. Table 
4.10 provides a comparison of the pharmacokinetic values 
derived by Levy (1967) and those of the present study. The 
other pharmacokinetic parameters (k 12' k21 ) derived from 
intravenous data describing drug distribution were also 
unaffected by posture. Rowland & Tozer (1980c) suggest that 
the distribution of certain drugs may be perfusion or 
diffusion rate controlled. Benzylpenicillin falls into the 
latter category and is therefore unlikely to be affected by 
regional changes in blood flow occurring with posture. 
In previous studies of the effects of posture on the 
disposition of the penicillins, Levy (1967) in a 
pharmacokinetic analysis of the report by Schmidt & Roholt 
(1966) who administered benzylpenicillin intramuscularly, 
determined that the rate constant for non-renal elimination, 
k , was significantly increased and the fraction of the dose 
excreted unchanged was significantly lower in ambulation 
than in bedrest. These findings might reflect changes in 
metabolism or changes at the absorption site. More 
recently, Roberts & Denton (1980) studied the effects of 
posture on orally administered amoxycillin. They observed 
an increased total body clearance of amoxycillin during 
bedrest but this assumed that there was no change in the 
bioavailability of the drug with change in posture. In the 
intramuscular dosing phases of the present 'study, the area 
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Table 4.10 Comparison of pharmacokinetic data from Levy (1967) with data determined in this study 
Parametera Ambulation 	 Bedrest 
vp m 
IV IM LEVY IV IM LEVY 
t, 	(min) 113 
f 
V 	(1) 
CL
R 
(ml/min) 
CL
NR 
(ml/min) 
53.6 	± 	32.3 
0.63 	± 	0.12 
38.63 	± 	30.39 
309.4 	± 	93.4 
178.0 	± 	51.3 
52.5 
0.46 
36.4 
264.3 
233.6 
± 	11.7 
± 	0.12 
± 	10.6 
_ 	99.7 
± 	81.3 
50.4 
0.67 
37 
340 
166.5 
54.2 	± 	36.1 
0.58 	± 	0.17 
46.97 	± 	44.58 
324.1 	± 	145.3 
218.2 	± 	66.5 
50.9 
0.55 
42.0 
314.6 
236.9 
±-19.3 
± 	0.09 
± 	18.9 
± 	87.4 
± 	108.4 
55.8 
0.82 
47 
480 
101.8 
a Parameters as defined in Table 4.3 
under the plasma benzylpenicillin concentration versus time 
curve during bedrest was significantly less than during 
ambulation. This AUC reflects both availability and 
clearance (Equation 4.8). Neither availability nor total 
body clearance (estimated using intravenous data) were found 
to be significantly altered by changes in posture. The lack 
of change highlights the intra-individual variability in 
benzylpenicillin kinetics. Significant changes are observed 
when only a single parameter such as AUC is compared on two 
occasions. The modification of this data by incorporating 
other data from the intravenous phases of the study (and its 
associated error) results in a loss of the statistical 
difference between bedrest and 'ambulation. Thus, the data 
available does not allow the source of the difference in AUC 
to be determined. The pharmacokinetic parameters 
(bioavailability, rate of absorption, mean absorption time) 
describing the absorption of intramuscular benzylpenicillin, 
were derived using both intramuscular and intravenous data 
and, therefore, have a greater error than would be 
associated with the direct determination of a single 
parameter. However, if posture-dependent changes in 
absorption kinetics do occur but not be shown by this study, 
these changes must be quite small and are not likely to be 
clinically significant. 
The mean renal clearances of benzylpenicillin found in this 
study (Tables 4.3 & 4.5) are intermediate between glomerular 
filtration and renal plasma flow and are consistent with the 
suggestion that benzylpenicillin is removed from the body by 
both active tubular secretion and glomerular filtration 
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(Barza & Weinstein, 1976). 
Levy (1967) determined that the renal clearance of 
benzylpenicillin was significantly increased in bedrest, but 
posture had no effect on total body clearance and Roberts & 
Denton (1980) observed both an increased renal clearance and 
increased total body clearance of amoxycillin during 
bedrest. 
Although, following intramuscular administration of 
benzylpenicillin, six of the eight subjects had a higher 
renal clearance of benzylpenicillin during bedrest than 
during ambulation, this trend was not sufficient for the 
difference to be significant. No trend was observed when 
the drug was administered intravenously. Levy (1967) and 
Roberts & Denton (1980) suggested that the changes in renal 
clearance observed in their studies may be due to changes in 
renal blood flow with changes in posture. Several 
haemodynamic changes occur with changes in posture such as 
haemoconcentration, decreased plasma volume (Hagan et al, 
1978) and reduced renal blood flow (Selkurt, 1963) in the 
upright subject. 	According to Equation 4.5, the renal 
clearance of benzylpenicillin is dependent on renal blood 
flow. If it is assumed that the renal intrinsic clearance 
and red blood cell - plasma partition coefficient for 
benzylpenicillin are unaffected by posture, and using the 
mean data for renal clearance (Table 4.3) and a bedrest 
renal plasma flow of 650 ml/min (Roberts & Denton, 1980), a 
decrease in renal plasma flow on adopting an upright posture 
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of approximately 28% is estimated from Equation 4.5. In the 
intravenous phases of this study this decrease was only 
about 10%. Roberts & Denton (1980) calculated a decrease in 
renal plasma flow of approximately 40% for their subjects 
and for the data of Levy (1967). The level of exercise as 
well as posture can influence renal plasma flow. In the 
supine position, the renal plasma flow is 15-20% higher than 
in the erect position with no exercise (Selkurt, 1963). 
During light to moderate exercise, renal plasma flow 
decreased by 15-27% compared to supine renal plasma flow 
(Chapman et al, 1948). As the level of exercise increases, 
the renal plasma flow decreases even further (Radigan & 
Robinson, 1949). The ambulant subjects in the present study 
only undertook light exercise, being confined mostly to the 
room in which the study was conducted or walking in a 
corridor. The larger decline in renal plasma flow in 
ambulant subjects estimated by Roberts & Denton (1980) may 
reflect a greater level of exercise undertaken in the 
ambulatory phase of their study than in the present study. 
From the results of the present study, it appears that 
posture per se or a change of posture accompanied by light 
exercise is insufficient to alter the renal clearance of 
benzylpenicillin. During the course of this study, Breiby 
et al (1983) reported a study on the effect of posture 
(bedrest and sitting at rest) on the pharmacokinetics of 
ampicillin following intravenous administration of the drug. 
They observed changes in distribution but no significant 
changes in clearance with change in posture. In that study, 
measurement of the glomerular filtration rate and renal 
blood flow failed to show any significant changes with 
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change in posture from lying down to sitting at rest. 
The'present study demonstrates that, although significant 
differences may be found with posture using measurements 
from extra-vascular studies alone, these differences 
disappear when intravenous data are used to gain a greater 
insight into the reasons for these differences. The results 
do suggest, however, that the absorption kinetics of 
benzylpenicillin after intramuscular administration is 
independent of posture. The major source of the posturally 
determined differences in plasma AUC appear to be 
differences in the clearance. Although this study showed a 
trend towards reduced renal clearance in upright 'subjects
undertaking light exercise when compared to bedrested 
subjects, the change failed to reach significance. The 
changes in the pharmacokinetics of the penicillins with 
changes in posture observed by other workers are probably 
related to the level of exercise undertaken by the subjects 
in those studies. 
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CHAPTER 5 
SULPHAMETHOXAZOLE and TRIMETHOPRIM 
5.1: INTRODUCTION 
5.1.1: DRUG PROFILES 
Both trimethoprim and sulphamethoxazole are broad-spectrum 
antibiotics with activity against gram-negative and gram-
positive microorganisms. However, their action is 
bacteriostatic rather than bactericidal. Sulphamethoxazole 
interferes in the bacterial folic acid metabolism by 
competing with para-aminobenzoic acid and thus blocking the 
biogenesis of dihydrofolate. Trimethoprim inhibits 
dihydrofolate reductase by competing with dihydrofolate 
(Brumfitt, Hamilton-miller & Kosmidis, 1973). This 
sequential blockade of tetrahydrofolate production is 
thought to be the cause of the synergistic action observed 
when these antibiotics are combined (Brumfitt et al, 1973). 
Trimethoprim, in vitro, is 10 to 40 times more active, 
weight for weight, than sulphamethoxazole and it has been 
found that similar ratios (1:10 to 1:40) of trimethoprim to 
sulphamethoxazole provide optimal synergism (Brumfitt et al, 
1973). To achieve these ratios in plasma, trimethoprim and 
sulphamethoxazole are given in a fixed 1:5 ratio (co-
trimoxazole). Recently, it has been suggested that 
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trimethoprim has some bactericidal effects and its 
combination with sulphamethoxazole antagonizes these effects 
rendering 'the combination bacteriostatic (Friesen, Hekster & 
Vree, 1981). Also, there is some uncertainty as to whether 
the combination is synergistic or merely additive (Friesen 
et al, 1981). 
Co-trimoxazole is particularly effective in the treatment of 
urinary tract infections, pneumocystis and otitis media and 
provides a valuable second line agent for the treatment of 
many other infections. 
This combination of trimethoprim and sulphamethoxazole is 
generally well tolerated. The majority of reported 
reactions are gastrointestinal or dermatological and these 
are usually minor. Toxicity is seldom life-threatening and 
is usually completely reversible. •Friesen et al (1981) 
suggest that most of the reported adverse reactions to the 
sulphamethoxazole-trimethoprim combination are due to 
sulphamethoxazole. 
5.1.2: ASSAYS 
A number of analytical methods have been used for the 
determination of trimethoprim in biological fluids including 
microbiological (Bushby & Hitchings, 1968), 
spectrofluorometric (Schwartz, Koechlin & Weinfeld, 1969; 
Lichtenwalner et al, 1979) and high-performance liquid 
chromatography (Weinfeld & Macasieb, 1979; Watson et al, 
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1980). The most widely used assay for the determination of 
sulphonamides in biological fluids has been a colorimetric 
assay based on the Bratton-Marshall reaction (Bratton & 
Marshall, 1939) but, recently, high-performance liquid 
chromatographic methods have been developed for sulphonamide 
determination (Johnson, Jeter & Clairborne, 1975; Sharma, 
Perkins & Bevill, 1976) and for determination of both 
trimethoprim and sulphamethoxazole (Vree et al, 1978a; Bury & 
Mashford, 1979; Gochin, Kanfer & Haigh, 1981). Only the 
methods of Vree et al (1978a) and Gochin et al (1981) also 
quantitate the major metabolite of sulphamethoxazole, N 4 - 
acetylsulphamethoxazole. The method of Gochin et al (1981) 
used solvent extraction in the 'preparation of samples while 
that of Vree et al (1978a) uses protein precipitation. For 
the present study, protein precipitation was chosen for its 
speed and simplicity, however the extensive dilution used by 
Vree et al (1978a) was undesirable. Using standard protein 
precipitation techniques, neither the mobile phase of Vree 
et al (1978a) nor that of Gochin et al (1981) gave sufficient 
resolution of the compounds from endogenous peaks. 
Consequently a new assay was developed. 
5.1.3: PHARMACOKINETICS 
Both trimethoprim and sulphamethoxazole are well absorbed 
after oral administration although there is considerable 
individual variation in absorption rates (Patel & Welling, 
1980). 
These two drugs have quite different physico-chemical 
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properties. Sulphamethoxazole (a weak acid, pKa 5.6) is 
less lipid-soluble than trimethoprim (a weak base, pKa 7.3) 
so does not distribute as extensively into tissues. 
Trimethoprim preferentially enters certain tissues, 
particularly the kidney, liver, spleen and prostate 
(Brumfitt et al, 1973). Consequently, trimethoprim has a 
much greater volume of distribution (100 to 200 1) than 
sulphamethoxazole (12 to 18 1) (Patel & Welling, 1980). The 
different distribution characteristics of the two drugs 
results in a sulphamethoxazole : trimethoprim ratio in the 
plasma ranging from 16:1 to 31:1 when a standard ratio of 
5:1 is administered (Patel & Welling, 1980). In the tissues 
this beneficial ratio is lost due to the poor penetration of 
sulphamethoxazole. Both drugs bind to plasma proteins, 
trimethoprim being approximately 45% bound and 
sulphamethoxazole 66% bound. 
Both drugs are metabolised but to quite different extents. 
Only about 20% sulphamethoxazole is excreted unchanged in 
the urine while approximately 60% of the dose is excreted as 
N 4 -acetylsulphamethoxazole and 15% as glucuronides (Rieder, 
1973). Trimethoprim is only about 20% metabolised with the 
remainder of the dose being excreted unchanged in the urine. 
A number of metabolites have been described for trimethoprim 
(Rieder, 1973). As the excretion of both compounds is 
relatively slow, the elimination half-life of 
sulphamethoxazole being 7-9 hours and that of trimethoprim 
being 6-17 hours in patients with normal renal function, the 
combination is usually administered on a twice daily basis. 
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The renal clearances of both sulphamethoxazole and 
trimethoprim are dependent on urinary pH with the renal 
clearance of sulphamethoxazole also being dependent on urine 
flow (Vree et al, 1978b; Craig & Kunin, 1973). 
Since differences in the pharmacokinetics of drugs do occur 
in bedrest, sleep and ambulation, it is of some importance 
to study the influence of these factors on drugs such as 
trimethoprim and sulphamethoxazole which have markedly 
different physico-chemical properties yet are administered 
in a fixed combination. 
5.2: ANALYSIS 
5.2.1: MATERIALS AND METHODS 
5.2.1.1: Chemicals 
Sulphamethoxazole, N 4 -acetylsulphamethoxazole and 
trimethoprim were supplied by Roche Products, Dee Why, NSW. 
Methanol and acetonitrile were specially purified for HPLC 
and supplied by Waters Associates (Milford, MA, USA). All 
other chemicals were analytical grade. The water used was 
de-ionised and glass distilled. 
5.2.1.2: HPLC instrumentation and conditions 
Plasma assay: Reversed-phase HPLC was performed using a 
Waters M-6000A solvent delivery system fitted with a U6K 
injector. A pBondapak phenyl column (particle size 10 pm; 
300 mm x 3.9 mm I.D.; Waters Associates, Milford, MA, USA) 
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was used in combination with a guard column (pBondapak 
C
18
/PorasilB; Waters Associates, 23 mm x 3.9 mm I.D.). UV 
absorbance at 230 nm was monitored with a Waters Model 441UV 
absorption detector fitted with a cadmium lamp. The 
absorbance was recorded on a dual-channel Omniscribe 
recorder (Houston Instruments, Austin, TX, USA). Injections 
were made with a 100 pl Hamilton syringe. The mobile phase 
was 0.067M phosphate buffer (pH 5.9) and acetonitrile 
(100:14) mixture. The flow rate was 1.8 ml/min. 
Urine assay: This assay was performed using, a Constametric 
1 HPLC pump (Laboratory Data Control), fitted with a 
Rheodyne injector, an ODS-HC SIL-X-1 column (particle size 
10 pm; 250 mm x 26 mm ID; Perkin Elmer, Norwalk, CONN, USA) 
and a guard column (Spherisorb C 18 ; Phase Sep, Clwyd, UK; 23 
mm x 3.9 mm ID). UV absorbance at 230 nm was monitored with 
a Perkin Elmer LC55 Spectrophotometer (Perkin Elmer, 
Norwalk, CONN, USA). The absorbance was recorded on a Curken 
Chart. Recorder (Curken Scientific Inc, Danbury, CONN, USA). 
Injections were made using a 25 pl Hamilton syringe. The 
mobile phase was 0.067M potassium dihydrogen phosphate 
solution (pH 4.2) and acetonitrile mixture (100:6.6). The 
flow rate was 1.5 ml/min. 
5.2.1.3: Sample preparation 
Plasma assay: A 400 pl aliquot of plasma was transferred 
into a glass tube (disposable borosilicate glass culture 
tubes; Kimble, IL, USA). To this was added 200 pl methanol 
and 40p1 perchloric acid (33%) solution. The sample was 
vortex mixed for 1 minute then centrifuged at 1500 g for 5 
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minutes. An aliquot (100 pl) of clear supernatant was injected 
onto the column. 
Urine assay: Equal volumes (200 pl) of urine sample and 
acetonitrile were added to a glass tube, vortex mixed for 1 
minute then centrifuged at 1500 g for 10 minutes. An aliquot 
(10p1) of the clear supernatant was injected onto the 
column. 
5.2.1.4: Preparation of standard curves 
Plasma standards were prepared by spiking drug-free plasma 
with known amounts of aqueous solutions of 
sulphamethoxazole, N 4 -acetylsulphamethoxazole, and 
trimethoprim. The standards were prepared such that those 
containing high concentrations of sulphamethoxazole had low 
concentrations of N 4 -acetylsulphamethoxazole and vice versa, 
as might be observed in clinical samples. The concentration 
range of the standards were sulphamethoxazole, 1.0 - 50.0 
mg/1; N 4 -acetyl-sulphamethoxazole, 0.5 - 20.0 mg/1; 
trimethoprim, 0.2 - 5.0 mg/l. The standards were then 
assayed in the described manner. Urine standards were 
prepared in a similar manner in drug-free urine to produce 
concentrations of 6.25 - 100 mg/1, 12.5 - 200 mg/1 and 6.25 
- 100 mg/1 for sulphamethoxazole, N 4 -acetylsulphamethoxazole 
and trimethoprim, respectively. Standard curves were 
prepared by plotting the peak height of drug versus 
concentration. 
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5.2.2: RESULTS 
5.2.2.1: Plasma assay 
Chromatograms of blank plasma and plasma spiked with 
sulphamethoxazole, N 4 -acetylsulphamethoxazole and 
trimethoprim are shown in Figure 5.1. The three compounds 
were well separated from each other and free from 
interference by endogenous peaks. The retention times were 
7.8 min, 9.7 min, 14.7 min for N 4 -sulphamethoxazole, 
sulphamethoxazole and trimethroprim, respectively. Peak 
heights and plasma concentrations were linearly related for 
each of the three compounds over the concentration range 
studied (r>0.99) (Figure 5.2). Sensitivity was 0.1 mg/1 for 
N
4 -acetylsulphamethoxazole, 0.2 mg/1 for sulphamethoxazole 
and 0.075 mg/1 for trimethoprim. 
Recovery was assessed by assaying aqueous and plasma 
standard solutions in the described manner and comparing the 
resultant peak heights. The recovery of sulphamethoxazole 
and trimethoprim were found to be 103 ± 4.9% (S.D.) and 96.6 
± 4.6% (S.D.), respectively over the range of concentrations 
used for the standard curves. The recovery of N 4 - 
acetylsulphamethoxazole was lower [85.3 ± 3.6% (S.D.)]. 
However, the extent of recovery was consistent as indicated 
by the reproducibility of the assay. The intra- and inter-
day reproducibility of the assay are shown in Table 5.1. 
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Figure 5.1 Chromatograms of (a) blank plasma and (b) plasma 
from the same subject spiked with N 4 -acetylsulphamethoxazole 
(AcSMZ) 5mg/1, sulphamethoxazole (SMZ) 10mg/1, and 
trimethoprim (TMP) 0.5mg/1 
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Figure 5.2 Standard curves for 0 sulphamethoxazole (SMZ), 
Li N 4 -acetylsulphamethoxazole (AcSMZ) and 
(TMP) in plasma 
0 trimethoprim 
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Table 5.1 	Intra- and inter-day variation in the assay of 
trimethoprim (TMP), sulphamethoxazole (SMZ) and N 4 -acetyl-
sulphamethoxazole (AcSMZ) in plasma. 
Compound 	Concentration 	CV(%) 
(mg/1) 	Intra-day 	Inter-day 
(n = 6) (n = 10) 
TMP 5.0 
2.0 
1.0 
0.5 
0.2 
1.20( 
4.61 
4.40 
3.01 
9.80 
11.97 
12.55 
12.19 
8.06 
SMZ 50.0 
20.0 
10.0 
5.0 
2.0 
1.57 
1.74 
1.86 
2.24 
1.77 
7.33 
9.03 
7.53 
8.82 
AcSMZ 	20.0 	2.71 
	
10.0 2.14 	6.90 
5.0 	1.46 6.25 
i.0 1.48 	6.96 
1. 0 
	 2.32 6.19 
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5.2.2.2: Urine assay 
Chromatograms of blank urine and urine from a subject 
following oral administration of co-trimoxazole are shown in 
Figure 5.3. Using this system the compounds eluted in a 
sequence different from the plasma assay. The retention 
times were trimethoprim, 5.0 min; sulphamethoxazole, 9.3 
min; and N 4 -acetylsulphamethoxazole, 18.5 min. There was no 
interference from endogenous peaks. Standard curves 
obtained by plotting the peak height of each compound versus 
their respective concentration were linear (r>0.99) over 
all the concentration ranges studied (Figure 5.4). The assay 
limits for trimethoprim, sulphamethoxazole and N 4 - 
acetylsulphamethoxazole were 4 mg/1, 5 mg/1 and 10 mg/1, 
respectively. The intra- and inter-day reproducibility of 
the assay are shown in Table 5.2. 
5.2.3: DISCUSSION 
The described methods provide simple, rapid means for 
assaying trimethoprim, sulphamethoxazole and its major 
metabolite, N 4 -acetylsulphamethoxazole in biological fluids. 
These methods are well suited to the clinical monitoring of 
the drugs. 
The sample preparation methods for both plasma and urine are 
simple. Given that the sensitivity of the assay is 
sufficient, HPLC allows direct injection of plasma and urine 
onto the column. However, doing so allows large amounts of 
contaminants into the system. The most common methods of 
sample preparation are solvent extraction or protein 
114 
CD 
() 
        
        
        
        
        
        
        
      
ff 
 
    
    
2 5 2 	' 	' I 0 15 10 6 0 	25 2 	' 0 15 10 
minutes minutes 
Figure 5.3 Chromatograms of (a) blank urine and (b) urine 
from the same subject collected from 0 - 12 hours after oral 
administration of 800 mg sulphamethoxazole and 160 mg 
trimethoprim. The estimated urine concentrations are 
trimethoprim (TMP) 32.88 mg/1, sulphamethoxazole (SMZ) 
64.91 mg/1, N 4 -acetylsulphamethoxazole (AcSMZ) 131.3 mg/1 
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Figure 5.4 Standard curves for 0 sulphamethoxazole (SMZ), 
o trimethoprim (TMP) and A N 4 -acetylsulphamethoxazole (AcSMZ) 
in urine 
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Table 5.2 	Intra- and inter-day variation in the assay of 
trimethoprim (TMP), sulphamethoxazole (SMZ) and N 4 -acetyl-
sulphamethoxazole (AcSMZ) in urine. 
Compound Concentration 
(mg/1) Intra-day 
(n 	= 	6) 
CV(%) 
Inter-day 
(n 	= 	11) 
TMP 100 2.39 5.41 
50 4.51 
25 2.88 4.91 
12.5 7.86 
6.25 13.74 (n = 9) 
SMZ" 100 5.11 6.15 
50 7.09 
25 2.54 8.27 
12.5 7.45 
6.25 12.69 (n = 9) 
AcSMZ 200 2.36 6.69 
100 7.04 
50 5.67 11.30 
25 6.33 
12.5 13.07 (n = 9) 
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precipitation (Li Wan Po & Irwin, 1980). Solvent extraction 
has been used by some workers in sample preparation for the 
assay of trimethoprim alone or with sulphamethoxazole and 
N
4
-acetylsulphamethoxazole (Gochin et al, 1981; Ascalone, 
1981; Watson et al, 1980; Weinfeld & Macasieb, 1979). 
Solvent extraction frequently achieves higher sensitivity 
but is relatively slow. Protein precipitation is rapid and 
has been used in co-trimoxazole assays by Vree et al (1978a) 
and Bury & Mashford (1979). Commonly used protein 
precipitants are trichloroacetic acid, tungstic acid, 
perchloric acid and acetonitrite (Li Wan Po & Irwin, 1980; 
Giese, 1983). Vree et al (1978a) diluted the serum samples 
ten fold with water before adding sufficient perchloric acid 
solution to dilute it a further five times. Using this 
dilution they found the recovery of sulphamethoxazole to be 
88 ± 4% and trimethoprim 83 ± 2%. The recovery was less if 
the sample was not diluted. Bury & Mashford (1979) used 
trichloroacetic acid (4 M) to precipitate proteins, 
requiring only 50 pl to be added to 1 ml plasma sample. 
However, their method required separate chromatographic 
conditions to assay trimethoprim and sulphamethoxazole. The 
recovery of sulphamethoxazole was only 81%. In the present 
study, trichloroacetic acid, acetonitrile and perchloric 
acid were tested as potential protein precipitants. 
Trichloroacetic acid was found to produce an interfering 
peak and acetonitrile caused poor drug peak shape especially 
at low drug concentrations. Perchloric acid was chosen but 
methanol was also added to remove any protein bound drug. 
This combination of methanol and perchloric acid has been 
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used successfully previously (Rumble, Roberts & Wanwimolruk, 
1981). 
In this study the detection wavelength was 230 nm. This 
wavelength was also used by Gochin et al (1981) and Watson 
et al (1980) because at this wavelength the absorbance of 
trimethoprim is about five times that of sulphamethoxazole 
on a weight basis (Gochin et al, 1981). This is important 
as the plasma concentration ratio of sulphamethoxazole to 
trimethoprim is approximately 20:1. Vree et al (1978a) used 
a wavelength of 225 nm while Bury & Mashford (1979) used 254 
nm. These wavelengths are not optimal for trimethoprim. 
This was confirmed by a UV scan of solutions of trimethoprim 
and sulphamethoxazole in mobile phase. 
The system used for plasma assay was tested for suitability 
for assaying urine samples. There was some interference 
from endogenous peaks which may have been overcome by pH 
manipulation. A change of laboratories necessitated using 
different equipment for the assay of urine samples, so, 
greater manipulation of pH and acetonitrile content of the 
mobile phase was necessary to assay the compounds in urine 
using the ODS-HC SIL-X-1 column. Experience with the two 
columns shows that the method is suitable for phenyl or C 18 
columns with some variation in pH or proportion of 
acetonitrile. 
This method was found to provide consistent results over 
several weeks of routine use with low interday variability. 
This variability was reduced further by assaying several 
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standards each day. 
5.3: PHARMACOKINETIC STUDY 
5.3.1: CLINICAL PROTOCOL 
5.3.1.1: Subjects 
Six healthy, young adult volunteers (three male, three 
female) aged 19-29 years, participated in the study. Prior 
to the investigation, a detailed \ medical history was taken. 
No participants gave a history of drug allergy, liver or 
renal disease or any concurrent illness. Physical 
examination, haematological tests and liver and kidney 
function tests were normal for all subjects. Each subject 
gave informed consent and approval was obtained from the 
Human Ethics Committee of the University of Tasmania before 
commencing the study. 
5.3.1.2: Procedure 
Co-trimoxazole (800 mg sulphamethoxazole and 160 mg 
trimethoprim; Bactrim DS, Roche, Dee Why, Australia) was 
administered as a single oral dose with 250 ml water on 
three separate occasions - during daytime bedrest, 
immediately prior to sleep (about midnight) and during 
daytime ambulation. No food or drink was permitted for two 
hours before and two hours after dosing. At least two weeks 
separated each study. 
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5.3.1.3: Sample Collection 
An indwelling catheter was inserted into an antecubetal vein 
approximately one hour before dosing. Subjects then adopted 
the posture required for the study. This posture was 
strictly maintained for the duration of the study. 5 ml 
blood samples were collected into heparinised tubes at 0, 
10, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, 600, 720 
minutes after dosing (blood collection ceased after 600 
minutes during the sleep study). The samples were 
centrifuged and the plasma drawn off then stored at -20°C 
until assayed. Urine was collected 0-12, 12-24, 24-48 and 
48-72 hours (0-10, 10-24, 24-48, 48-72 hours for sleep 
study). The volume and pH of each sample was measured and 
an aliquot retained at -20°C until assayed. Samples were 
assayed according to the method described above. 
5.3.1.4: Pharmacokinetics and statistical analysis 
For each drug, where there were four or more data points 
following the measured peak drug concentration, the overall 
elimination rate constant (8) was determined from the slope 
of the terminal linear segment of a semilogarithmic plot of 
plasma concentration versus time. The elimination half-life 
(t 1 ) was calculated in the usual manner (t 1 = 0.693/8). The 
area under the plasma concentration-time curve from time 
zero to ten hours (AUC 10 ) was calculated by the trapezoidal 
rule. For data where 8 had been calculated, the area under 
the plasma concentration-time curve from time zero to 
infinity (AUC.) was calculated by the trapezoidal rule and 
adding the usual "area to infinity" correction (last 
estimate of plasma drug concentration divided by 8). The 
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apparent total body clearance (CL B ) for these data was 
calculated by dividing the dose by the AUC . Since the 
drugs were administered orally in the present study, the 
volumes of distribution for the drugs could not be estimated 
directly. Where 	had been calculated, the present data did 
enable the ratio of the apparent volume of distribution (V) 
to the extent of absorption into the systemic circulation 
(F) for that drug to be calculated according to Equation 
5.1. 
V/F -  	 (5.1) 
(3.AUC 
where D is the oral dose. 
The rate of absorption was assessed from the observed time 
to peak drug concentration and the observed peak drug 
concentration. The amount of drug excreted unchanged in the 
urine during the study period (ten or twelve hours) and the 
volume of urine excreted during that time were used to 
determine the urinary excretion rate for each drug for each 
phase of the study. Urine flow rate was calculated as the 
mean value observed during the first urine collection period 
following drug administration. 
Statistical comparison of the effect of bedrest, sleep and 
ambulation on various pharmacokinetic parameters was made by 
analysis of variance or t-test as appropriate. 
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5.3.2: RESULTS 
The mean plasma sulphamethoxazole concentration versus time 
profiles during ambulation, bedrest and sleep are presented 
in Figure 5.5 and the profiles for its major metabolite N 4 - 
acetylsulphamethoxazole and for trimethoprim are shown in 
Figures 5.6 and 5.7, respectively. The individual 
experimental and pharmacokinetic data for these drugs during 
ambulation, bedrest and sleep are presented in Tables 5.3, 
5.4 and 5.5, respectively. 
The mean data for each of the states of ambulation, bedrest 
and sleep are presented in Table 5.6. As the plasma 
collection periods of this study were only conducted over 
10-12 hours as this was the maximum time interval that 
subjects could remain asleep or ambulant, calculation of the 
terminal elimination rate constant and, thus, terminal half-
life (t i ), total body clearance (CLB ) and volume of 
distribution (V/F) for sulphamethoxazole was not possible 
for many subjects, especially during the sleep phase of the 
study. Sufficient post-peak concentration data were 
available for determination of these parameters for 
trimethoprim for all subjects in each of the three phases of 
the study. There were no significant differences between 
the values obtained during ambulation, bedrest and sleep for 
any of the pharmacokinetic parameters for sulphamethoxazole 
and trimethoprim (Table 5.6) except for the half-life 
and total body clearance for sulphamethoxazole. The half-
life of sulphamethoxazole during bedrest was significantly 
shorter than during ambulation and the clearance of the drug 
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Figure 5.5 Mean (±SD) plasma sulphamethoxazole 
concentration - time profiles observed during A ambulation, 
o bedrest and 0 sleep in six healthy volunteers following 
oral administration of 800mg sulphamethoxazole with 160mg 
trimethoprim 
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Figure 5.6 Mean (±SD) plasma concentration versus time 
profiles of the major metabolite of sulphamethoxazole (N 4 - 
acetylsulphamethoxazole) during A ambulation, 0 bedrest 
and 0 sleep following administration of 800mg 
sulphamethoxazole and 160mg trimethoprim to six healthy 
subjects 
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Figure 5.7 Mean (±SD) plasma trimethoprim concentrations 
found in six healthy volunteers following administration of 
160mg trimethoprim with 800mg sulphamethoxazole during 
A ambulation, 0 bedrest and 0 sleep 
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Table 5.3 Experimental and pharmacokinetic data describing the disposition of 
sulphamethoxazole, N 4 -acetylsulphamethoxazole and trimethoprim in ambulant subjects. 
Parametera 	 Subject 
CW 	HM 	JS 	AA 	CD 	JG 
Age 	(y) 19 	19 	21 19 29 21 
Sex 
Sulphamethoxazole 
AUC
10 
(min.mg/1) 	. 23492 	23566 	29960 17686 24186 20284 
t11 	(h) 8.95 	9.31 	18.63 9.17 10.79 13.28 
CL
B 
(ml/min) 	16.63 	13.88 	6.96 22.68 15.36 15.42 
V/F 	(1) 12.89 	11.19 	11.23 18.00 14.36 17.72 
C 	(mg/1) 	60.02 	52.51 	65.36 49.30 56.36 56.57 
t 	(min) 190 	340 	192 160 92 135 
N4 -acetylsulphamethoxazole 
AUC
10 
(min.mg/1) 	4548 	2989 	3776 3984 4844 2123 
Trimethoprim 
AUC
10 
(min.mg/1) 	812.85 	837.38 	881.03 716.43 670.28 805.25 
t11 	(h) 11.00 	7.49 	11.55 . 6.75 9.69 15.82 
CLB 	(ml/min) 	89.12 	101.86 	77.23 132.95 116.81 74.41 
V/F 	(1) 84.88 	66.14 	77.23 77.75 100.70 101.93 
C 	(mg/1) 	1.73 	1.88 	1:93 1.58 1.46 2.92 P 
t 	(min) 50 	135 	45 100 62 35 P 
a AUC I0 - area under plasma concentration-time curve from time 0 to 	10 hours; 
t, - half-life; CL B - total, body clearance; V/F - apparent volume of distribution (V 
divided by the fraction of dose absorbed (F); C - observed peak plasma drug 
concentration; t - observed time to C following drug administration. 
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Table 5.4 Pharmacokinetic data describing the disposition of sulphamethoxazole, 
N 4 -acetylsulphamethoxazole and trimethoprim in bedrested subjects. 
Parametera 	 Subject 
CW HM JS AA CD JC 
Sulphamethoxazole 
AUC 10 	(min.mg/1) 19739 17909 24558 21147 16758 18775 
t, 	(11) 7.80 N/A 13.43 5.95 8.31 9.17 
CLB (ml/min) 18.32 N/A 11.27 25.99 24.14 21.04 
V/F 	(1) 12.38 N/A 13.10 13.40 17.37 16.70 
C 	(mg/1) 65.77 40.64 57.02 47.66 43.97 42.39 
t 	(min) 240 480 360 120 180 240 P 
N4 -acetylsulphamethoxazole 
AUC 10 	(min.mg/1) 3311 2419 3020 3916 3391 2434 
Trimethoprim 
AUC 10 	(min.mg/1) 668.30 773.93 948.95 791.73 343.65 663.65 
til 	(h) 9.87 9.96 12.29 11.44 4.60 12.98 
CLB (ml/min) 105.61 88.68 69.61 88.62 301.27 97.05 
V/F 	(1) 90.26 76.45 74.05 87.74 120.03 109.04 
C 	(mg/1) 1.91 1.81 2.29 1.86 0.74 1.73 
t 	(min) 90 240 120 60 90 63 
a Parameters as defined in Table 5.3 
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Table 5.5 Pharmacokinetic data describing the disposition of sulphamethoxazole, 
N4 -acetylsulphamethoxazole and trimethoprim in sleeping subjects. 
Parameter a 	 Subject 
CW HM JS AA CD JC 
Sulphamethoxazole 
AUC 10 	(min.mg/1) 	24232 
t i 	(h) N/A 1 
CLB (ml/min) 	N/A 
V/F 	(1) N/A 
24643 
11.00 
14.18 
13.50 
27370 
N/A 
N/A 
N/A 
16667 
N/A 
N/A 
N/A 
18974 
9.71 
17.78 
14.94 
15050 
N/A 
N/A 
N/A 
C 	(mg/1) 	53.70 
t 	(min) 360 
51.34 
180 
69.34 
360 
34.20 
360 
42.50 
240 
36.26, 
360 
N4 -acetylsulphamethoxazole 
AUC 10 	(min.mg/1) 	4677 4848 3153 3886 3462 1584 
Trimethoprim 
AUC 10 	(min.mg/1) 	804.93 864.68 896.75 510.20 551.65 498.68 
t11 	(h) 14.44 10.69 8.68 18.93 12.69 21.39 
CLB 	(ml/min) 	71.35 91.73 90.84 87.83 161.42 75.84 
V/F 	(1) 89.19 84.94 68.30 143.98 177.38 140.44 
C 	(mg/1) 	1.84 2.03 2.50 ' 	1.08 1.48 1.28 
t 	(min) 120 65 120 90 120 180 
a Parameters as defined in Table 5.3 
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Table 5.6 Comparison of mean estimates (± SD) of pharmacokinetic parameters for 
sulphamethoxazole, N 4 -acetylsulphamethoxazole and trimethoprim from data in 
Tables 5.3, 5.4 & 5.5. 
Parametera 	' Ambulation 	Bedrest 	Sleep 
Sulphamethoxazole 
AUC 10 (min.mg/1) 23196 ± 	4142 19814 ± 	2769 21156 ± 4948 
t1/2 	(h) 11.69 ± 	3.77 8.93 ± 	2.76
b N/A 
CL
B (ml/min) 15.16 ± 	5.05 20.15 ± 	5.77
b N/A 
V/F 	(1) 14.23 ± 	3.05 14.59 ± 	2.27 N/A 
C 	(mg/1) 56.69 ± 	5.63 49.58 ± 	9.84 47.89 ± 	13.10 
t 	(min) 184.8 ± 	84.7 270.0 ± 	130.0 310.0 ± 	79.7 
N4 -acetylsulphamethoxazole 
AUC
10 
(min.mg/1) 3711 ± 	1011 3082 ± 	584 3602 ± 	1190 
Trimethoprim 
AUC
10 (min.mg/1) 787.20 ± 	78.72 698.37 ± 	202.56 687.82 ± 	186.82 
t1/2 	(h) 10.43 ± 	3.26 10.19 ± 	3.00 14.47 ± 	4.87 
CL
B 
(ml/min) 98.73 ± 	23.04 125.14 ±.87.11 96.50 ± 	32.88 
V/F 	(1) 84.77 ± 	14.15 92.93 ± 	18.20 117.37 ± 	42.65 
C 	(mg/1) 1.92 ± 	0.52 1.72 ± 	0.52 1.70 ± 	0.52 
t 	(min) 71.2 ± 	38.6 110.5 ± 	67.1 115.8 ± 	38.5 
a Parameters as - defined in Table 5.3 
p<0.05 (paired t-test) 
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during bedrest was greater than during ambulation. 
Insufficient sulphamethoxazole data were available from the 
sleep phase of the study for comparison. 
The urinary data is presented in Table 5.7. One subject (CD) 
failed to collect all urine in the sleep phase of the study. 
The urinary excretion rates of both sulphamethoxazole and 
N
4
-acetylsulphamethoxazole during bedrest were significantly 
greater than during sleep but not ambulation. The urinary 
excretion rate of trimethoprim showed no significant 
differences between ambulation, bedrest and sleep. The 
urine pH during bedrest was significantly higher than either 
ambulation and sleep while the urine flow rate and the 
urinary sulphamethoxazole:trimethoprim ratio during bedrest 
were significantly higher than during ambulation and sleep. 
5.3.3: DISCUSSION 
The disposition of both sulphamethoxazole and trimethoprim 
following a single dose is best described by a two-
compartment open model (Naber, Vergin & Weigand, 1981). 
Since the present study was conducted over a relatively 
short period for which subjects could maintain sleep or 
ambulation and the drugs were administered orally, good 
estimates of the individual kinetic constants describing the 
biexponential pharmacokinetics could not be obtained. In 
the case of trimethoprim, sufficient data were available in 
each of the three states to enable calculation of the model-
independent pharmacokinetic parameters of terminal half- 
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Table 5.7 Mean (± SD) urinary drug excretion rate, urine flow and urine pH 
during ambulation, bedrest and sleep 
Parametera 	Ambulation 
(n 	= 	6) 
Bedrest 
(n 	= 	6) 
Sleep 
(n 	= 	5) 
R 	(SMZ) 	(mg/h) 	3.69 ur 
R 	(AcSMZ) 	(mg/h) 	13.13 ur 
R 	(TMP) 	(mg/h) 	3.52 ur 
Urine pH 	6.44 
Urine flow (ml/min) 	1.05 
SMZ:TMP 	1.08 
± 	1.64 
± 	4.34 
± 	0.91 
± 	0.35 
± 	0.38 
± 	0.49 
	
7.72 	± 	4.12 b 
16.39 	± 	4.86 b 
3.63 	± 	1.47 
7.25 	± 	0.26 c 
1.49 	± 	0.43 b 
2.30 	± 	1•25 b 
1.71 
7.92 
3.37 
6.38 
0.89 
0.50 
± 	0.93 
± 	3.37 
± 	0.59 
± 	0.50 
± 	0.28 
± 0.28 
a Rur - renal excretion rate; SMZ - sulphamethoxazole; 
AcSmz - N 4 -acetylsylphamethoxazole; TMP - trimethoprim; 
SMZ:TMP - ratio of amount of sulphamethoxazole excreted in the urine during 
the first urine collection period to the amount of trimethoprim excreted 
over the same time. 
Bedrest significantly different from sleep but not from ambulation. 
(p<0.05) 
Bedrest significantly different from sleep, ambulation. 
(p<0.05) 
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life, clearance and apparent volume of distribution. For 
sulphamethoxazole, these parameters could not be calculated 
for all subjects during bedrest and sleep. Non- 
compartmental pharmacokinetic analysis of the data using 
statistical moment theory was not possible due to 
insufficient data describing the elimination phase for each 
compound. Yamaoka, Nakagawa and Uno (1978) calculated that 
if elimination phase data is acquired until the plasma 
concentration of a drug is 5% of its maximum, the error in 
mean residence time (MRT) is about 10%. In this study the 
final measured concentrations of sulphamethoxazole and 
trimethoprim are about 50% of their maxima, so, the error in 
calculating the mean residence time would be unacceptable. 
5.3.3.1: Sulphamethoxazole pharmacokinetics 
The mean plasma sulphamethoxazole concentrations obtained at 
various times following oral administration of 800 mg of 
sulphamethoxazole, in combination with trimethoprim, to 
healthy subjects (Figure 5.5) are similar to those reported 
previously (Naber et al, 1981; Welling et al, 1973; Vergin 
et al, 1981). The values for the pharmacokinetic parameters 
determined for sulphamethoxazole (Table 5.6) are also 
similar to those reported by other workers (Spreux-
Veroquaux et al, 1983; Naber et al, 1981; Kremers, Duvivier 
& Heusghem, 1974). Although no significant differences were 
found for the rates of sulphamethoxazole absorption between 
the states (Table 5.6), the actual mean values for time to 
reach peak plasma concentration (t n ) suggest that absorption 
occurs more rapidly during ambulation than during bedrest 
and that absorption is slowest during sleep. This is 
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probably related to slower gastric emptying in supine 
subjects than in ambulant subjects. Similar slower rate of 
absorption in supine subjects has been observed for other 
drugs by other workers (Roberts & Denton, 1980; Nimmo & 
Prescott, 1978). The faster mean rate of absorption during 
ambulation results in a higher mean peak concentration (Cp) 
of sulphamethoxazole. However, the peak concentrations for 
each of the three states were not significantly different. 
Due to the slower absorption rate and shorter plasma 
monitoring period during the sleep phase of the study, it 
was not possible to determine the terminal half-life, total 
clearance or volume of distribution for enough subjects to 
make comparisons between the values for these parameters 
obtained during sleep and those obtained during bedrest and 
ambulation (Table 5.5). Comparison of the disposition of 
sulphamethoxazole during bedrest and ambulation showed that 
the terminal half-life was significantly shorter and the 
total body clearance was significantly higher during bedrest 
than during ambulation. The apparent volume of distribution 
divided by the extent of absorption (V/F) was not 
significantly affected by the change in posture. This 
faster elimination of the drug during bedrest was associated 
with a significantly higher urine flow rate and a 
significantly higher urinary pH (Table 5.7). 
Sulphamethoxazole is a weak acid with a pKa of 5.6 (Wormser, 
1978). With these physico-chemical properties, the renal 
excretion may be assumed to be dependent on urinary pH and 
uring flow (Cafruny, 1977). Welling et al (1973) 
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administered urinary acidifier or alkaliniser at the same 
time as drug administration to subjects and observed that 
alkaline loading increased the urinary recovery of 
sulphamethoxazole and that the half-life was shorter but not 
significantly so. More recently, Vree et al (1978b) found 
that when the urine was maintained alkaline (pH 7 to 8) the 
half-life of sulphamethoxazole was shorter (9 h) than when 
the urine was maintained at a pH of 5.5 to 6.0 (11 h). Vree 
et al (1978b) also found that at a particular urinary pH 
(alkaline or acid), the renal excretion rate of 
sulphamethoxazole was influenced by urine flow. In the 
present study, the relationship between the urinary 
excretion rate of sulphamethoxazole on urinary pH and urine 
flow was examined (Figures 5.8 and 5.9). There was a linear 
relationship between the urinary excretion rate and urine 
flow (r = 0.790, p<0.001) and between the urinary excretion 
rate and urine pH (r = 0.790, p<0.001). The urinary 
excretion rate of N
4 -acetylsulphamethoxazole appeared not to 
be influenced by urine flow rate (r = 0.389, p = 0.123) and 
only marginally by urine pH (r = 0.686, p<0.01). Vree et al 
(1978b) and Vree et al (1979) found the renal excretion rate 
of N 4 -acetylsulphamethoxazole was not influenced by either 
urine flow rate or urine pH. The pKa of N 4 -acetyl-
sulphamethoxazole is 5.00 and its lipid solubility is about 
one-fifth that of sulphamethoxazole (Vree et al, 1979). The 
renal elimination pf weakly acidic drugs with pKa between 3.0 
and 7.5 is influenced by urinary pH if the undissociated 
form is lipid soluble (Cafruny, 1977). Although the lipid 
solubility of N 4 -acetylsulphamethoxazole is lower than that 
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of the parent drug, Vree et al (1978b) and Vree et al (1981) 
found that its renal clearance (40-60 ml/min) in subjects 
with normal renal function was considerably lower than the 
glomerular filtration rate suggesting some reabsorption 
occurred in the tubule. Thus, it is not unexpected that pH 
should have some influence on its elimination rate. 
5.3.3.2: Trimethoprim pharmacokinetics 
' From the plasma trimethoprim concentration-time profiles 
(Figure 5.7) and the calculated values for the pharmacokinetic 
parameters (Table 5.6), the disposition of trimethoprim 
appears to be unaffected by posture or sleep. 
The peak concentration of trimethoprim was always achieved 
earlier than the peak concentration of sulphamethoxazole. 
This phenomenon has been observed by other workers (Rogers et 
al, 1980; Naber et al, 1981; Kaplan et al, 1973). The peak 
concentrations and values for the other pharmacokinetic 
parameters appear to be in close agreement with published 
values for subjects with normal renal function (Patel & 
Welling, 1980; Wormser, 1978). 
In contrast to sulphamethoxazole, the urinary excretion rate 
of trimethoprim appears to be unaffected by changes in urine 
flow (r = 0.198, p = 0.447) or by changes in urine pH 
(r = 0.272, p = 0.291). Sharpstone (1969) and Bergan & 
Brodwall (1972) also found no correlation between urine flow 
and renal excretion of trimethoprim but several workers have 
observed a significant relationship between urine pH and the 
renal elimination of trimethoprim (Craig & Kunin, 1973; 
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Bergan & Brodwall, 1972; Welling et al, 1973). However, in 
those studies many urine samples had quite low pH (pH<6.0) 
whereas, in the present study, only one subject had a 
urinary pH of less than 6.0 during the study period. Bergan 
& Brodwall (1972) suggest that at urinary pH greater than 
6.2 net reabsorption occurs and it is only below this point 
that net tubular secretion takes place. It may be that the 
pH of the urine samples in the present study were too high 
for a relationship between the renal excretion rate of 
trimethoprim and urine pH to be evident. 
The dependence of sulphamethoxazole elimination on urine pH 
and urine flow results in a significantly greater urinary 
sulphamethoxazole:trimethoprim ratio during bedrest than 
during sleep. Craig & Kunin (1973) reported ratios greater 
than 5:1 in alkaline urine. The highest ratio in the 
present study was 4.14:1. Variations in the 
sulphamethoxazole:trimethoprim ratio in urine are unlikely 
to have any clinical consequences over a normal dosing 
interval as the concentrations of both drugs are usually 
several times the minimum inhibitory concentration required 
for most susceptible organisms found in the urine (Patel & 
Welling, 1980). 
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CHAPTER 6 
PARACETAMOL 
6.1: INTRODUCTION 
6.1.1: DRUG PROFILE 
Paracetamol (acetaminophen) is an effective and widely used 
analgesic and antipyretic agent. It has little anti-
inflammatory action at normal therapeutic doses used in 
humans although •an anti-inflammatory effect has been 
demonstrated at high doses in animal models (Flower, Moncada 
& Vane, 1980). The specific mechanism of action of 
paracetamol is unknown. It has been suggested, however, 
that its analgesic and antipyretic effects and lack of anti-
inflammatory effect may be associated with an ability to 
inhibit prostaglandin synthetase in the brain but little 
ability to inhibit peripheral tissue prostaglandin 
synthetase (Jackson, MacDonald & Cornett, 1984). 
At recommended doses, serious adverse reactions to 
paracetamol are uncommon. Following massive overdose of 
paracetamol, liver damage ranging from minor to severe may 
occur. The liver damage occurs when liver glutathione 
levels drop to less than 20-30% of normal during the 
metabolism of paracetamol to the cysteine and mercapturic 
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acid conjugates. When this occurs, a reactive metabolite 
binds to hepatic proteins leading to hepatic necrosis 
(Davis, Labadarios & Williams, 1976). Treatment with N-
acetylcysteine within 10 to 24 hours of overdosage can 
prevent hepatic damage occurring. Some recent reports 
indicate that cimetidine, but not ranitidine, inhibits the 
metabolism of paracetamol to the reactive metabolite and 
prevents liver glutathione depletion (Abernathy et al, 1983; 
Mitchell, Schenker & Speeg, 1984). Cimetidine may be a 
suitable agent in the treatment of paracetamol overdosage. 
6.1.2: ASSAYS 
There are several assay techniques available for the 
determination of paracetamol in biological fluids. The 
hepatotoxicity of paracetamol when ingested in large amounts 
has lead to many of the assays being developed for the 
determination of plasma concentrations following overdose 
rather than following therapeutic doses. Non-
chromatographic methods include UV spectrophotometry and 
colorimetry. These methods are more susceptible to 
interference and poor or variable extraction than 
chromatographic methods. Also, determination of individual 
metabolites is not possible. Chromatographic techniques 
have included both gas-liquid chromatography and high-
performance liquid chromatography. Non-chromatographic, 
gas-liquid chromatographic and early high-performance liquid 
chromatographic methods have been reviewed by Wiener (1978). 
A survey of recent reports on paracetamol pharmacokinetics 
(Divoll et al, 1982; Abernathy et al, 1983; Ameer et al, 
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1983; Anderson et al, 1983; Mitchell et al, 1983; Miners et 
al, 1984b) showed that high-performance liquid 
chromatography was now the assay technique of choice. 
Ideally, for full pharmacokinetic studies, the assay methods 
used should be capable of measuring paracetamol metabolites 
as well as the parent drug in both plasma or serum and 
urine. Several HPLC methods have been described for the 
determination of paracetamol and its metabolites in urine 
(Howie et al, 1977; Knox & Jurand, 1977; Knox & Jurand, 
1978; Wilson et al, 1982; Miners et al, 1984a) but only 
those of Mrochek et al (1974) and Adriaenssens & Prescott 
(1978) are capable of measuring the paracetamol metabolites 
in plasma. 
The methods of Mrochek et al (1974) involves anion-exchange 
chromatography and takes 24 hours per sample. The method 
described below provides a rapid determination of 
paracetamol and its major metabolites, the sulphate and 
glucuronide conjugates, in serum. 
6.1.3: PHARMACOKINETICS 
Paracetamol is a moderately water-soluble and lipid-soluble 
weak acid with a pKa of 9.5, thus it is largely un-ionised 
in biological fluids. Paracetamol is rapidly absorbed from 
the small intestine, its onset and rate of absorption being 
dependent on the rate of gastric emptying (Clements et al, 
1978). A variable proportion of the dose is lost through 
first-pass metabolism and the bioavailability appears to be 
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dose-dependent, increasing from 63% after 500mg dose to 
almost 90% after lg and 2g doses (Rawlins, Henderson & 
Hijab, 1977) and, also, to be formulation-dependent with a 
650mg dose having 87% bioavailability when administered as a 
solution but only 79% when given as tablets (Ameer et al, 
1983). 
Paracetamol distributes throughout most tissues and fluids 
and has a volume of distribution of approximately 0.9 1/kg 
(Perucca & Richens, 1979). There is no apparent binding of 
paracetamol to plasma proteins at drug concentrations found 
after therapeutic doses. At higher plasma concentrations 
similar to those observed after toxic doses, paracetamol is 
15-21% bound to plasma proteins (Gazzard et al, 1973). 
Paracetamol is extensively metabolised with only 2 to 5% of 
a dose being excreted unchanged in the urine. Following a 
therapeutic dose the major metabolites are the sulphate 
(33%). and glucuronide (54%) conjugates with the cysteine 
(4%) and mercapturate (5%) being relatively minor 
metabolites (Forrest et al, 1979). In neonates and young 
children, glucuronidation is a less important metabolic 
pathway for the elimination of paracetamol; paracetamol 
sulphate being the major metabolite (Miller, Roberts & 
Fischer, 1976). 
Shively & Vesell (1975) suggested that there is a temporal 
variation in the elimination of paracetamol. However, a 
recent study by Malan, Moncrieff & Bosch (1985) found that 
the time of dosing had no effect on the disposition of 
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paracetamol. It has been reported that the absorption of 
paracetamol may be slower during sleep and bedrest than 
during ambulation (Mattok & McGilveray, 1973; Nimmo & 
Prescott, 1978) but the effect of posture was not separated 
from that of sleep. Prescott (1975) reported that the 
plasma concentrations of paracetamol in convalescent 
patients in bed were higher than in ambulant healthy 
volunteers after an oral dose of 1.5g. The lower plasma 
paracetamol concentrations in the ambulant healthy 
volunteers were attributed to an increase in the volume of 
distribution produced by exercise performed by these 
subjects (Prescott, 1975). 
In the present study, the effects of posture and sleep on 
the disposition of paracetamol and its metabolites were 
examined. Paracetamol is a model for drugs with low hepatic 
extraction ratios which undergo type II metabolism. 
6.2: ANALYSIS 
6.2.1: MATERIALS & METHODS 
6.2.1.1: Chemicals 
Paracetamol and its metabolites, paracetamol sulphate, 
glucuronide and cysteine were supplied by Sterling 
Laboratories, Newcastle on Tyne, Great Britain. Methanol 
and acetonitrile were specially purified for HPLC and 
supplied by Waters Associates (Milford, MA, USA). Water was 
de-ionised then glass distilled. All other materials used 
in the determination of paracetamol and its metabolites in 
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biological fluids were of analytical quality. 
6.2.1.2: HPLC instrumentation and conditions 
Reversed-phase high-performance liquid chromatography was 
performed using a Waters model M6000A solvent delivery 
system fitted with a U6K injector, precolumn (pBondapak 
C
18
/Porasil B; 23 mm I.D.; Waters Associates, Milford, MA, 
USA) and a pBondapak C
18 
column (particle size 10 pm; 300 mm 
x 3.9 mm I.D; Waters Associates). UV absorbance at 254 nm 
was monitored with a Waters Model 450 variable wavelength 
absorbance detector. The absorbance was recorded on a dual-
channel Omniscribe recorder (Houston Instruments, Austin, 
TX, USA). Injections were made with a 25 pl Hamilton 
syringe. 
6.2.1.3: Serum paracetamol and metabolites 
For the determination of serum paracetamol, paracetamol 
glucuronide and paracetamol sulphate, the mobile phase was 
0.1M potassium dihydrogen phosphate - methanol - formic acid 
(90%) - ethylacetate mixture (90:15:0.15:0.1) at a flow rate 
of 1 ml/min. 
Samples were prepared by adding 20 pl perchloric acid (30%) 
containing 2 mg/ml phenol (internal standard) to 200 pl 
serum. The sample was vortex mixed for one minute then 
centrifuged at 1500g for 5 minutes. 10p1 of the supernatant 
was injected onto the column. 
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6.2.1.4: Urinary paracetamol and metabolites 
Urinary paracetamol and its glucuronide, sulphate and 
cysteine conjugates were determined by the method of Miners 
et al (1984a). In this method the mobile phase was 2.5% 
acetonitrile and 97.5% 20 mmo1/1 orthophosphoric acid 
(adjusted to pH4.7 with potassium hydroxide) at a flow rate 
of 2 ml/min. 
Urine samples were pretreated by adding 20 pl perchloric 
acid (30%) to 200 pl urine, vortex mixing for 1 minute, then 
centrifuging. 5 pl of the supernatant was injected onto the 
column. 
6.2.1.5: Preparation of standard curves 
Plasma standards were prepared by spiking drug-free plasma 
with known amounts of freshly-prepared aqueous solutions of 
paracetamol and its metabolites to produce concentrations of 
1-20 mg/1 for each compound. The standards were then 
assayed in the described manner. Urine standards were 
prepared in a similar manner to produce concentrations of 5- 
500 mg/1 of each compound. Standard curves for plasma were 
prepared by plotting the peak height ratio (drug:internal 
standard) versus concentration and standard curves for urine 
were prepared by plotting the peak height of the compound 
versus concentration. 
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6.2.2: RESULTS & DISCUSSION 
Chromatograms of blank serum and serum from a subject 
following oral administration of 500 mg paracetamol are 
shown in Figure 6.1. The retention times for paracetamol 
glucuronide, paracetamol sulphate, paracetamol and phenol 
were 4.8, 7.2, 8.8 and 17 minutes, respectively. The peak 
for the glucuronide metabolite eluted on the shoulder of the 
plasma peak which made accurate determination of low 
concentrations of this metabolite difficult. To make the 
glucuronide peak more visible the chart speed was 5 mm per 
minute for the first 5.5 minutes following each injection 
then reduced to 2.5 mm per minute (Figure 6.1). Figure 6.2 
shows chromatograms of blank urine and urine following oral 
administration of 500 mg paracetamol. The retention times 
for paracetamol glucuronide, paracetamol sulphate, 
paracetamol cysteine and paracetamol were 3.0, 6.8, 8.2 and 
9.2 minutes, respectively. These retention times are in the 
same sequence but slightly longer than those observed by 
Miners et al (1984a). 
Several HPLC assays for the determination of paracetamol 
either alone or with its metabolites use UV detection at 254 
nm (Knox & Jurand, 1977; Adriaenssens & Prescott, 1978; 
Demotes-Mainard, 1984) while all other assay reports 
reviewed use UV detection between 240 nm and 250 nm (Howie 
et al 1977; Horvitz & Jatlow, 1977; O'Connell & Zurzola, 
1982; Wilson et al, 1982). Using 254 nm,in this assay 
provided satisfactory sensitivity without interfering 
endogenous peaks. 
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Figure 6.1 Chromatograms of (a) blank serum and (b) serum 
from the same subject 120 minutes after oral administration 
of 500mg paracetamol. Estimated concentrations are: 
paracetamol glucuronide (pg) 3.06 mg/1; paracetamol sulphate 
(ps) 3.59mg/1; paracetamol (p) 4.00 mg/l. The internal 
standard is phenol (ph). The arrow indicates both change in 
chart speed and change in absorbance scale 
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Figure 6.2 Chromatograms of (a) blank urine and (b) urine 
from the same subject collected 0 - 24 hours after oral 
administration of 500mg paracetamol. Estimated 
concentrations are: paracetamol glucuronide (pg) 484.8 mg/1; 
paracetamol sulphate (ps) 216.2 mg/1; paracetamol cysteine 
(pc) 25.7mg/1; paracetamol (p) 8.7mg/1, 
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To reduce contamination of the column with serum proteins 
and lipids, serum samples maybe pretreated, usually by 
extraction of the drug using an immiscible organic solvent 
or by precipitation of the plasma proteins by a suitable 
agent. Commonly used agents to precipitate serum proteins 
include trichloroacetic acid, tungstic acid, perchloric acid 
and acetonitrile (Li Wan Po & Irwin, 1980; Giese, 1983). In 
the assay of paracetamol, trichloroacetic acid (Howie et al, 
1977) and perchloric acid (Adriaenssens & Prescott, 1978) 
have been used. Most other HPLC assays for paracetamol in 
plasma or serum have used solvent extraction. Protein 
precipitation has the advantages of being rapid and simple 
and, providing that release of 'drug from plasma proteins is 
complete, is not subject to variable extraction of the drug. 
Paracetamol is not bound to plasma proteins at therapeutic 
plasma concentrations (Forrest et al, 1982), so protein 
precipitation is an excellent manner of sample preparation 
for the assay of this drug. 
The mobile phase used in this assay was derived from 
information in the report by Knox & Jurand (1977) which 
studied the influence of changes in mobile phase components 
on the retention patterns of urinary paracetamol and its 
metabolites. The final choice of mobile phase provided 
optimum resolution of the compounds from endogenous peaks 
and each other. 
Over the concentration ranges studied (0-20 mg/1 for serum 
and 0-500 mg/1 for urine), linearity of response was found 
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Figure 6.3 Serum standard curves for Li paracetamol, 
0 paracetamol glucuronide and 0 paracetamol sulphate 
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Figure 6.4 Urine standard curves for A paracetamol, 
0 paracetamol glucuronide, 0 paracetamol sulphate, 
<> paracetamol cysteine 
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to be good (r>0.99) (Figures 6.3 & 6.4) and consistently 
reproducible for standard curves based on the peak height 
. 	J ratio of drug to internal standard for plasma and on peak 
height alone for urine. Under the conditions of this assay, 
the assay limits for paracetamol and its glucuronide and 
sulphate metabolites in serum were approximately 0.5, 1.0 
and 1.0 mg/1, respectively. In urine, the assay limits were 
approximately 5 mg/1 for the cysteine and sulphate 
metabolites and 2 mg/1 for paracetamol and the glucuronide 
metabolite. 
6.3: PHARMACOKINETIC STUDY 
6.3.1: CLINICAL PROTOCOL 
6.3.1.1 Subjects 
Eight healthy male adult volunteers aged 21 to 26 years 
participated in the study. Prior to the investigation, a 
detailed medical history was taken. No subjects gave a 
history of liver or renal disease and physical examination, 
haematological tests and liver and renal function tests were 
normal for all subjects. Before the study was commenced, 
informed consent was obtained from each subject and approval 
was obtained from the Human Ethics Committee of the 
University of Tasmania. 
6.3.1.2 Procedure 
Each subject ingested 500mg paracetamol (Sterling 
Laboratories, Sydney, Australia) with 250m1 of water on 
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three separate occasions - during ambulation in the day, 
during bedrest in the day and immediately prior to sleep at 
night (usually at 12 midnight). No food was permitted for 
two hours before and two hours after dosing. At least one 
week elapsed between each study. 
6.3.1.3: Sample collection 
Blood was sampled via an indwelling catheter, inserted into 
an antecubetal vein approximately one hour before dosing. 
The catheter permitted blood sampling with minimum 
disturbance to the subject. Patency of the catheter was 
maintained by flushing it with a small volume of heparanised 
saline (10 IU/ml) after each blood sample was taken. Blood 
was collected at 0, 15, 30, 45, 60, 90, 120, 180, 240 and 
360 minutes after dosing. During blood collection, the 
first 1.0m1 was drawn separately and discarded then the 
remainder of the sample was collected into non-heparinised 
tubes and allowed to clot at room temperature before being 
centrifuged. Serum was drawn off with a Pasteur pipette and 
stored at -20° until assayed. All urine excreted by the 
subjects over 24 hours after dosing was collected and 
pooled. An aliquot of the pooled urine was retained and 
stored at -20° until assayed. 
6.3.1.4: Pharmacokinetic and statistical analysis 
The overall elimination rate constant (8) for paracetamol 
was determined from the slope of the terminal linear segment 
of a semilogarithmic plot of serum concentration versus 
time. This was then used to calculate the elimination half-
life (t, = 0.693/8). The apparent total body clearance 
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(CL B ) of paracetamol was calculated by dividing the dose by 
the area under the serum paracetamol versus time curve from 
zero to infinity (AUC). The AUC was determined by the 
trapezoidal rule (Gibaldi & Perrier 1982b). The time to 
peak serum paracetamol concentration and the peak serum 
paracetamol concentration were used to assess the rate of 
absorption of the drug. As paracetamol was administered 
orally, its apparent volume of distribution could not be 
estimated directly. The ratio of the apparent volume of 
distribution for paracetamol (V) to its availability to the 
systemic circulation (F) was calculated according to 
Equation 6.1. 
V/F -  	 (6.1) 
8.AUC 
where D is the administered oral dose. 
The non-compartmental pharmacokinetic parameter, mean 
residence time (MRT), based on statistical moment theory, 
was calculated from the AUC and AUMC and is given by 
Equation 6.2 (Gibaldi & Perrier, 1982b): 
AUMC 	fmtCdt 
MRT - 
AUC 	orCdt 
	 (6.2) 
The areas under the serum paracetamol glucuronide and 
paracetamol sulphate versus time curves were also calculated 
by the trapezoidal rule. As it was not possible to 
accurately determine the slope of the terminal portion of 
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CL = m AUCd 
AUCm CL . 	(m) 
the semilogarithmic plots of serum metabolite concentration 
versus time, this slope was assumed to be the same as that 
of the parent drug (Cummings, King & Martin, 1967) for the 
calculation of the "area to infinity" portion of the area 
under the curve (last estimate of serum metabolite 
concentration divided by 8). 
The renal clearance (CLR ) of paracetomol, paracetamol 
glucuronide and paracetamol sulphate were estimated from the 
ratio of amount of unchanged drug or metabolite excreted in 
the urine to infinite time (X u ) to the AUC for parent drug 
or metabolite (Equation 6.3). For this calculation, it was 
assumed that urine collected up to 24 hours was equivalent 
to infinite time. 
CL R 
co Xu  
AUC 
(6.3) 
As the metabolites, paracetamol glucuronide and paracetamol 
sulphate are eliminated renally and apparently not further 
metabolised, it was assumed that the renal clearance of the 
metabolite adequately described the total clearance of that 
metabolite. The clearance of formation (CL) was then 
calculated from the following equation (Rowland & Tozer, 
1980d) 
(6.4) 
Where CLm is the clearance associated with the metabolism of 
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parent drug to the particular metabolite, AUC m and AUCd are 
the areas under the serum concentration versus time curves 
for metabolite and parent drug, respectively, and CL(m) is 
the total clearance of that metabolite. 
Statistical comparisons of the effect of bedrest, sleep and 
ambulation on various pharmacokinetic parameters was made by 
one-factor analysis of variance with repeated measures 
(Ferguson, 1976). The source of significant differences was 
identified using a studentized range test. 
6.3.2: RESULTS 
The mean serum paracetamol levels versus time profiles are 
shown in Figure 6.5. There were no significant differences 
between the profiles. 
The individual experimental and pharmacokinetic data for 
paracetamol in subjects during ambulation, bedrest and sleep 
are shown in Tables 6.1, 6.2 and 6.3, respectively. The 
mean data for each of the parameters determined during each 
state are shown in Table 6.4. 
There were no significant differences between the values 
obtained during ambulation, bedrest and sleep for any of the 
pharmacokinetic p'arameters determined except the non-
compartmental parameter, mean residence time (MRT). For 
this parameter the values obtained during ambulation and 
sleep were significantly different (p<0.05) but differences 
between ambulation and bedrest and between bedrest and sleep 
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Table 6.1 Experimental and pharmacokinetic data describing the disposition kinetics of 
paracetamol in ambulatory male subjects 
Parametera Subject 
2 3 4 5 6 7 8 
Age 	(y) 23 21 22 26 21 23 23- 23 
Weight 	(kg) 72.3 71.8 61.0 70.5 72.7 76.4 72.7 68.1 
AUC. (min.mg/1) 1837 1287 2052 1359 2102 1472 987 1102 
i-■ t 	(min) 130.0 148.3 144.4 115.5 177.8 114.9 103.1 98.8 (xi 1/2 
k.0 CL B 	(ml/min) 272.1 388.4 243.7 368.0 237.9 339.7 506.8 453.6 
V/F 	(1/kg) 0.71 1.16 0.83 0.87 0.84 0.74 1.04 1.29 
CL R 	(ml/min) 4.46 N/A 1.56 3.39 7.90 3.67 3.04 4.54 
mRT 	(min) 192.5 231.5 246.6 145.0 292.4 160.7 155.8 139.3 
f 0.022 N/A 0.015 0.011 0.032 0.018 0.013 0.028 
Urine flow (ml/min) 1.61 1.29 0.45 0.54 0.72 0.42 0.52 1.94 
_ 	Urine pH 6.0 5.5 5.1 5.7 5.7 5.5 6.4 5.7 
a AUC - area under the serum paracetamol concentration versus time curve from zero to 
infinite 	time; 	t 1/2 	- half-life; CL B - total body clearance; V/F - apparent volume of 
distribution (V) divided by the fraction of dose absorbed (F); CL R - renal clearance; 
MRT - mean residence time; f - fraction of dose excreted unchanged in urine 
Table 6.2 Experimental and pharmacokinetic data describing the disposition kinetics of 
paracetamol in male subjects during bedrest 
Parameter a Subject 
1 2 3 4 5 6 7 8 
Age 	(y) 23 21 22 26 21 23 23 23 
Weight 	(kg) 72.3 71.8 61.0 70.5 72.7 76.4 72.7 68.1 
AUC.(min.mg/1) 1836 1058 2534 1363 1679 1222 957 1053 
1-, • cs 
t, 	(min) 1 140.3 72.2 173.9 120.6 156:6 114.3 99.5 105.4 
C CLB (ml/min) 272.4 472.5 197.3 366.9 297.7 409.3 512.8 474.7 
V/F 	(1/kg) 0.76 0.69 0.81 0.91 0.92 0.88 0.01 1.44 
CL R 	(ml/min) 6.86 3.02 5.25 3.16 2.92 N/A 4.00 7.41 
MRT(min) 214.6 	193.9 	230.5 	173.4 	239.0 	190.7 	153.9 	177.4 
f 0.038 0.026 0.048 0.030 0.028 N/A 0.020 0.031 
Urine flow (ml/min) 	0.99 	3.00 	2.34 	1.84 	1.00 	3.74 	1.20 	2.28 
Urine pH 	6.6 	6.2 6.5 	5.8 7.1 	6.6 6.7 	7.1 
a Parameter definitions as in Table 6.1 
Table 6.3 Experimental and pharmaCokinetic data describing the disposition kinetics of 
paracetamol in male subjects during sleep 
Parameter a Subject 
1 2 3 4 5 6 7 8 
Age 	(y) 23 21 22 26 21 23 23 23 
Weight 	(kg) 72.3 71.8 61.0 70.5 72.7 76.4 72.7 68.1 
AUC 	(min.mg/1) 1766 1319 1899 1199 3014 1380 1131 1458 
F.- 
t, 	(min) 1 126.5 187.9 152.3 116.2 181.5 115.6 117.1 164.4 
cr■ CLB 	(ml/min) 283.1 378.9 263.3 417.0 165.9 362.2 442.2 343.0 
V/F 	(1/kg) 0.71 1.43 0.95 0.99 0.60 0.79 1.03 1.63 
CL R 	(ml/min) 2.55 2.58 1.84 4.50 1.96 3.98 4.78 1.85 
MRT 	(min) 213.8 295.2 229.3 261.7 267.4 188.5 238.0 223.2 
f 0.022 0.032 0.017 0.018 0.013 0.018 0.023 0.010 
Urine flow (ml/min) 0.65 1.50 0.43 0.88 0.63 0.86 1.07 0.58 
Urine pH 5.6 5.9 6.3 5.9 5.8 5.8 6.9 5.3 
a Parameter definitions as in Table 6.1 
Table 6.4 	Comparison of mean estimates (± SD) of pharmacokinetic 
parameters 	for paracetamol 
in Tables 	6.1, 	6.2 	and 6.3 
in eight male subjects from data 
Parameter a Ambulation Bedrest Sleep 
AUC 	(min.mg/1) 1525 ± 425 1465 ± 	531 1646 ± 	613 
t i (min) 129.1 ± 	26.6 122.8 ± 	32.8 142.2 ± 	30.3 
CL B (ml/min) 351.3 ± 	97.9 375.5 ± 	112.0 331.9 ± 	90.5 
V/F 	(1/kg) 0.94 ± 	0.21 0.92 ± 	0.23 1.02 ± 	0.35 
CL R (ml/min) 4.08 ± 	1.96 4.66 ± 	1.88 3.01 ± 	1.23 
MRT (min) 195.5 ± 	55.8 201.7 ± 	38.1 239.6 ± 	33.8 b 
0.020 ± 	0.008 0.032 ± 	0.009 0.019 ± 	0.007 
Urine flow(ml/min) 0.94 ± 	0.21 2.14 ± 0.32 c 0.83 ± 	0.12 
Urine pH 5.7 ± 	0.13 6.6 + 0.15 c 5.9 ± 	0.17 
a Parameter definitions as in Table 6.1 
b Sleep significantly different from ambulation but not 
bedrest (p<0.05) 
Bedrest significantly different from ambulation, sleep (p<0.01) 
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were not significantly different. It was found that the 
urinary flow rate and urinary pH of bedrested subjects were 
significantly greater than during either sleep or 
ambulation. 
In Table 6.5 the mean time to peak (t n ) for paracetamol and 
the mean peak serum paracetamol concentration (C r ) for 
ambulation, bedrest and sleep are shown. The mean times to 
peak for sleeping subjects were greater than for bedrest 
subjects which were greater than for ambulant subjects and 
the mean peak concentration for ambulant subjects were 
higher than for bedrest subjects which were higher than for 
sleeping subjects. However, owing to the large individual 
variation in these absorption parameters, these parameters 
were not found to be significantly different in any of the 
states. 
The mean serum paracetamol glucuronide levels versus time 
profiles and mean serum paracetamol sulphate levels versus 
time profiles are shown in Figures 6.6 and 6.7, 
respectively. Pharmacokinetic parameters determined for the 
metabolites are shown in Table 6.5. There were no 
significant differences between the renal clearances or the 
clearance of formation determined for either metabolite in 
each state of ambulation, bedrest or sleep. As can be seen 
from Figures 6.6 and 6.7 and Table 6.5, the mean time to 
peak concentration follows the same sequence as for the 
parent drug. Only the time to peak concentration for 
paracetamol glucuronide shows any significant difference 
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Table 6.5 Comparison of mean estimates (±SD) of pharMacokinetic parameters 
for paracetamol absorption and for paracetamol metabolites in eight male 
subjects. 
Parametera Ambulation Bedrest Sleep 
CP  paracetamol (mg/1) 
t paracetamol (min) P 
t 	glucuronide 	(min) P 
t 	sulphate 	(min) P 
glucuronide 	(min) t corr 
sulphate 	(min) t corr 
CL formation glucuronide(ml/min) 
CLformation sulphate 	(ml/min) 
CLR glucuronide (ml/min) 
CL R sulphate 	(ml/min) 
9.47 
35.6 
105.0 
96.9 
70.6 
39.4 
89.6 
105.0 
174.0 
125.0 
± 	4.18 
± 	27.7 
± 	22.6 
± 	33.5 
± 	24.6 
± 	33.0 
± 	30.3 b 
± 	39•9 b 
± 	115.8 
± 	65.2 
8.65 
54.5 
128.6 
84.4 
65.4 
31.3 
73.9 
73.6 
138.7 
85.5 
± 	2.64 
± 	29.7 
±. 48.0 
± 	42.4 
± 	55.6 
± 	18.8 
± 45.4 b 
± 29•9 b 
± 99.9 
± 28.0 
7.29 
72.0 
165.0 
97.5 
101.9 
28.1 
64.3 
88.0 
65.0 
105.3 
± 	2.67 
± 	53.5 
± 	62.1 c 
± 	54.5 
± 	54.7 
± 	32.5 
± 	19.0 
+ 	40.2 
+ 	21.5 
± 	30.6 
a C - peak serum paracetamol concentration; t - time to 
peak concentration for paracetamol or metabolites; 
CL 	- clearance of formation; CL R - renal clearance; formation 
= t p (metabolite) - t (paracetamol) corr 
n = 7 
sleep significantly different from ambulation but not bedrest qo<0.05 ) 
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with change of posture, the time to peak during sleep being 
significantly greater than the time to peak during 
ambulation. When the time to peak data for the metabolites 
are corrected for the time to peak for paracetamol, these 
differences disappear (Table 6.5). 
6.3.3: DISCUSSION 
The half-lives for paracetamol found in the three phases of 
this study (range 72.2 - 187.9 min.) are similar to those 
observed by many other workers (Forrest et al, 1979; 
Cummings et al, 1967; Shively & Vesell, 1975; Forfar et al, 
1980) following both oral and intravenous administration of 
the drug. The mean apparent body clearance and volume of 
distribution of paracetamol for ambulation, bedrest and 
sleep (Table 6.4) are also similar to those observed by 
other workers (Divoll et al, 1982; Shively & Vesell, 1975; 
Perucca & Richens, 1979). The non-compartmental 
pharmacokinetic parameter, mean residence time (MRT), has 
not been described previously for paracetamol. 
The present study showed no significant differences in the 
plasma concentrations of paracetamol during ambulation and 
bedrest. Significantly higher concentrations of paracetamol 
in bedridden convalescent patients than in ambulant 
volunteers has been reported by Prescott (1975), differences 
in the apparent volume of distribution being suggested as 
the explanation. As this study and an earlier one (Mattok & 
McGilveray, 1973) have failed to show any effect of posture 
on paracetamol disposition, the differences reported by 
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Prescott (1975) probably reflect either different subject 
characteristics or other effects. 
Shively & Vesell (1975) have reported that the disposition 
of paracetamol showed temporal variation. However, the 
changes are slight. After dosing at 6 am, the mean 
elimination half-life was 15% longer than the dose at 2 pm; 
the difference being attributed to a change in the apparent 
volume of distribution. The longer half lives also appeared 
to correspond to high plasma cortisol levels (Shively & 
Vesell, 1975). No significant differences in paracetamol 
disposition for the night time (sleep) and day time 
(bedrest) studies were observed in the present work, yet the 
times of dosing correspond to the times for minimal and 
maximal plasma cortisol levels (Moore Ede, 1973). Evidence 
of differences in the absorption rate between the states was 
found in this study. The mean residence time (MRT) was 
significantly longer during sleep than during ambulation 
(p<0.05) (Table 6.4). Other studies have also reported the 
absorption of paracetamol to be slower during sleep and 
bedrest than during ambulation (Mattock & McGilveray, 1973; 
Nimmo & Prescott, 1978). As V/F, elimination half life and 
body clearance of paracetamol do not differ significantly 
between the states of bedrest, ambulation and sleep (Table 
6.4), the differences in MRT probably reflect differences in 
mean absorption time (MAT) rather than mean disposition time 
(MRT IV )-(MRT = MAT + MRT IV ) (Riegelman & Collier, 1980). 
The differences in the times to peak concentration for 
paracetamol and its metabolites in the three states are also 
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consistent with absorption rate differences between sleep, 
bedrest and ambulation. Mean peak times of 72, 55 and 36 
min were found for paracetamol for the states of sleep, 
bedrest and ambulation, respectively (Table 6.5). The time 
to peak metabolite concentration (t n ) for paracetamol 
glucuronide was significantly longer during sleep than 
during ambulation (Table 6.5). However, when this was 
corrected for the time to peak serum paracetamol 
concentration, this difference disappeared. The time to 
peak paracetamol sulphate concentration showed no 
significant difference between any of the states. As the 
amount of total drug recovered from the urine during the 
study did not differ significantly between the states, 
changes in posture and sleep appear to have had no 
significant effect on the extent of paracetamol absorption. 
Other pharmacokinetic parameters for the major metabolites 
of paracetamol, paracetamol glucuronide and paracetamol 
sulphate, were not significantly altered by postural changes 
or sleep. Prescott (1980) reported the mean renal clearance 
of paracetamol sulphate and glucuronide to be 166 ml/min and 
130 ml/min, respectively, following a dose of 20 mg/kg. In 
the present study the mean ambulant renal clearances of 
these metabolites were similar (Table 6.5) although there 
was a large intersubject variation. The clearance of 
formation does not appear to have been reported elsewhere. 
The results of this study suggest that there are no 
significant changes in the disposition of paracetamol and 
its metabolites with changes in posture and sleep. The 
absorption of paracetamol tends to be slower in supine 
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subjects than in ambulant subjects. However, these changes 
are not likely to be of any clinical significance. 
An important implication of this study is that drugs falling 
into the category of low binding, low hepatic extraction 
ratio are unlikely to be affected by changes in posture or 
sleep. The lack of change in the pharmacokinetics of 
paracetamol and its conjugates is consistent with the known 
physiology of the body. For instance, both the basal 
metabolic rate and glomerular filtration rate appear 
relatively constant throughout the day and night (Wagner, 
1975). Changes in urine pH, urine flow and haemodynamics 
with change of posture or during sleep have been reported 
(Roberts & Denton, 1980) and it is the pharmacokinetics of 
drugs most dependent on these variables which are likely to 
show any changes with posture and/or sleep. 
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CHAPTER 7 
CONCLUSIONS 
7.1: POSTURE 
The findings of these - studies show that the pharmacokinetics 
of drugs can be modified by changes in posture. 
Posture appears to have only minor effects on oral 
absorption. The mean times to peak concentration for 
paracetamol, sulphamethoxazole, and trimethoprim were longer 
during bedrest than ambulation but not significantly so. 
Posture did not have any significant effects on the 
intramuscular absorption of benzylpenicillin. 
The distribution of the highly polar drug, gentamicin, was 
altered by changes in posture. On adoption of an upright 
posture, haemoconcentration occurs and there is a shift in 
blood flow away from the liver and kidney to the periphery. 
These changes in tissue perfusion and extravascular fluid 
may account for the larger volume of distribution for 
gentamicin observed in ambulant subjects than observed in 
supine subjects. The distribution of the other drugs 
studied appeared to be unaffected by changes in posture. 
The only drug studied with extensive hepatic elimination was 
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paracetamol which has a low hepatic extraction ratio. The 
elimination of paracetamol in ambulant subjects did not 
differ significantly from that in supine subjects. 
The effects of posture on the renal elimination of drugs 
depended on the disposition characteristics of the drugs. 
The higher urine pH and urine flow in bedrested subjects 
resulted in a shorter half-life and greater urinary 
excretion rate for sulphamethoxazole in supine subjects than 
in ambulant subjects. These results are in accordance with 
the physico-chemical properties of sulphamethoxazole, a weak 
acid of pKa 5.7. The urinary excretion rate of 
trimethoprim, a weak base, is also dependent on urine pH but 
is less sensitive to changes than sulphamethoxazole over the 
range of urine pH observed in these studies. Consequently, 
changes in posture did not affect the disposition of 
trimethoprim. 
Gentamicin is eliminated solely by glomerular filtration and 
has a low renal extraction ratio. As the glomerular 
filtration rate is not affected by posture or exercise 
(Breiby et al, 1983; Swartz & Sidell, 1973), the minor 
posture-dependent changes in clearance observed in these . 
studies are probably due to altered tissue uptake associated 
with modified distribution rather than variation in renal 
clearance. 
Moving from a supine to an upright position causes a 15-20% 
decrease in renal blood flow. Benzylpenicillin is an 
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example of drugs with high renal extraction ratios whose 
elimination may be influenced by changes in renal perfusion. 
In these studies, the renal clearance of benzylpenicillin 
was unaffected by change of posture. These findings suggest 
that the posture-dependent changes in renal clearance of the 
penicillins reported by Roberts & Denton (1980) and Schmidt 
& Roholt (1966) were due to a higher level of exercise in 
the ambulant phase of those studies which would further 
reduce renal blood flow. 
7.2: SLEEP 
In the studies where the effects of sleep were examined, 
sleep had, generally, the same effects on drug disposition 
as bedrest. 
7.3: FUTURE WORK 
As hepatic blood flow is altered by changes in posture, 
the effects of posture on the elimination of high hepatic 
extraction ratio drugs requires examination. Klotz & 
Ziegler (1982) reported that the total body clearance of 
midazolam was much higher in supine subjects than in 
ambulant subjects. It would be interesting to confirm their 
results using another drug with similar disposition 
characteristics. One of the difficulties in selecting a 
suitable drug is that many drugs with high hepatic clearance 
(such as propranolol, lignocaine, verapamil and hydralazine) 
are vasoactive and may affect their own disposition. 
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Exercise causes many haemodynamic changes and may be an 
important factor in the disposition of drugs. The findings 
of Swartz & Side11 (1973) and Swartz et al (1974) indicate 
that exercise may alter the disposition of drugs with either 
high renal clearance or high hepatic c1earance. Tissue 
perfusion is modified by exercise. Thi_s may alter the 
distribution of certain drugs. This has already been shown 
for digoxin (Pedersen et al, 1983) . Future studies could 
examine the effects of graded exercise on the disposition of 
drugs. 
Dettli & Spring (1966) observed an apparently much slower 
elimination of the highly protein—bound drug, 
sulphasymazine, when patients got out of bed before their 
blood sample time. This finding was attributed to the 
haemoconcentration that occurs on moving from a supine to an 
upright posture. For highly protein-bound drugs these 
changes could produce misleading results in blood-level 
monitoring and the pharmacokinetics of these drugs may 
appear altered by changes in posture. 	A systematic 
examination of the effects of posture on the blood levels 
and disposition of clinically important highly-bound drugs 
such as phenytoin and warfarin should be undertaken. 
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